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Abstract 
Background: Multimorbidity is a major challenge facing governments and health-
care systems worldwide due to increasing prevalence globally, the high consumption 
of resources and the implications for health care. Multimorbidity is commonly defined 
through a simple count of health conditions, using a cut-off of 2 or more or 3 or more 
conditions. There is also increasing interest in statistical approaches to definition. No 
consensus of the definition of multimorbidity yet exists, which hinders comparisons 
between studies and advancement of the field. The vast majority of studies have been 
conducted in clinical or age-restricted populations, with few representative population 
studies available. No studies have been performed to examine the association of 
multimorbidity and health status using different definitions of multimorbidity. 
Moreover, multimorbidity and its effect on productivity in the Australian working 
population, the health of which is central to the economic strength of the country, has 
not been well studied.  
Aims: The primary aim of this thesis was to assess the associations of multimorbidity 
with quality of life, health care service use, productivity losses and the related 
financial burden, particularly in the working population. Three different cross-
sectional data sets were interrogated and a systematic review was conducted. A 
secondary aim was to assess to what extent current large national prevalence surveys 
in Australia are fit for purpose in surveillance of multimorbidity and its correlates.  
Methods: The Australian National Survey of Mental Health and Wellbeing 2007 
were used in Study I (Chapter 3). The health-related quality of life (HRQoL) scores 
were measured using the Assessment of Quality of Life (AQoL-4D) instrument. The 
simple count (2+ & 3+ conditions) and hierarchical cluster methods were used to 
define/identify clusters of multimorbidity. Linear regression was used to assess the 
associations between HRQoL and multimorbidity as defined by the different methods. 
The data derived from the Australian National Health Survey (NHS) 2011-12 was 
used in Study II (Chapter 4) to understand how Australian employees use health 
ix 
service for a single disease when suffering from multimorbidity. The health service 
use was reported for each health condition in the NHS and thus it was impossible to 
tabulate service use by the disorder count. However, the NHS 2011-12 was a large 
population-based Australian data source including the health status, employment 
status and health service use of over 10 thousand working adults. This data was the 
latest available in Australia when we conducted this study. The employee self-
reported 2013 data derived from the partnering Healthy@Work (pH@W) survey of 
all state government employees in Tasmania (including 3,228 Australian employees) 
was used in Study III (Chapter 5) to assess the associations of multimorbidity on 
health-related productivity loss by sex as these associations influenced by sex were 
inconsistent. Data were weighted for non-response. Measures of absenteeism, 
presenteeism and lost productive time (LPT) were obtained from employees’ self-
reported data over a 28-day period. Analyses were stratified by sex, and negative 
binomial models were used to estimate the associations between multimorbidity and 
the lost productivity time. In Chapter 4 and 5, multimorbidity was defined as the co-
occurrence of 2+ chronic conditions out of a pre-specified list depending on the 
different surveys used. Study IV (Chapter 6) was a systematic review of costs-of-
illness (COI) studies of multimorbidity registered with Prospero (an international 
prospective register of systematic reviews). The search strategy combined key words 
related to multimorbidity, comorbidity and multiple chronic health conditions. The 
search was restricted to papers written in English and published since 2000 up to 
October 2016. The inclusion criteria were peer-reviewed cross-sectional, cohorts and 
modeling COI studies on multimorbidity, whereas the exclusion criterion was studies 
focusing on an index disease. The review summarized the current state of evidence 
and evaluated the quality of cost of illness studies of multimorbidity using the British 
Medical Journal Checklist for authors and peer reviewers of economic submissions. 
Results: Study I: HRQoL was negatively associated with multimorbidity regardless 
of the definition of multimorbidity used. Statistically significant clusters were 
identified through hierarchical cluster analysis and verified by sensitivity analysis. 
Study II: the prevalence of multimorbidity in the working population was 23.4% 
using two cut-off count method. Multimorbid employees with arthritis had higher 
adjusted arthritis-specific GP visit rates compared to employees with arthritis alone. 
x 
Similarly, multimorbid employees with CVD had higher adjusted CVD-specific 
specialist visit rates and CVD-specific other health professional visits than employees 
with CVD alone. Study III: the positive association of multimorbidity and LPT, and 
the significant differences in LPT between men and women reporting multimorbidity 
were identified. Both sexes with multimorbidity were more likely to have greater 
productivity loss due to absenteeism or presenteeism compared to those without, but 
female employees with multimorbidity were more likely to have lost productivity 
days due to presenteeism and absenteeism, compared to their male counterparts. The 
mean number of total days of health-related lost productive time in the past 4 weeks 
was 1.2 (SD=2.4) and 1.7 (SD=3.5) for male and female employees with 
multimorbidity, respectively, compared to 0.6 (SD=2.2) and 0.6 (SD=1.8) for males 
and females without multimorbidity. Both sexes with multimorbidity were more 
likely to have greater productivity loss due to absenteeism or presenteeism compared 
to those without, but female employees with multimorbidity had 40% and 30% more 
lost days due to absenteeism (PR=1.4, 95% CI 1.1-1.8) and presenteeism (PR=1.3, 
95% CI 1.0-1.6), respectively, compared to their male counterparts. However, there 
were no significant differences in days lost productivity between male employees 
with multimorbidity versus without multimorbidity. Study IV found that within 26 
included articles, the definition used in the 14 studies that clearly defined 
multimorbidity was limited to the two cut-off count method. The methodology used to 
derive costs differed markedly among the studies. Average annual costs per person 
with multimorbidity ranged from $US 49-$US 252,313. Using a two cut-off count 
method, the ratios of multimorbidity versus non-multimorbidity costs ranged from 2-
16 within 17 available studies; while using three cut-off method, the ratios ranged 
from 2-10 within 12 available studies. Among 10 studies providing a breakdown on 
costs, the largest proportion for multimorbidity was spent on inpatient or medication 
costs in non-societal perspective studies, and social care costs from the societal 
perspective. Costs-of-illness studies of multimorbidity were highly heterogeneous. 
The economic burden of multimorbidity was heavy for all age groups. 
Conclusions: These findings confirm multimorbidity as a significant public health 
issue in the general population, as well as in the workforce. Further, these findings 
provide three notable contributions. The first major contribution is theoretical, and 
xi 
refers to the definitions used for multimorbidity. Comparison of definitions shows that 
the count method is still useful due to its ease of calculation, but consistency is needed 
on whether a 2-disorder or 3-disorder cut-off is most useful. Hierarchical clustering 
could be used as a supplementary tool to capture the specific common clusters of 
multimorbidity. A uniform definition of multimorbidity is needed. The second major 
contribution is practical. This thesis has quantified the impact of multimorbidity on 
health care resource consumption in the Australian workforce and on productivity in a 
large Australia occupational cohort. The heavy economic burden of multimorbidity as 
shown in the systematic review suggests that multimorbidity will be more and more 
important in the future, especially with social changes related to delayed retirement. 
Finally, the results from the currently available datasets we used highlight the fact that 
the currently available data restrict the further exploration of multimorbidity. 
Standardisation of chronic disease surveillance methodologies in national prevalence 
surveys would aid in epidemiological investigation of multimorbidity in the general 
population.  
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Chapter 1 
 
Chapter 1. Introduction 
1.1 Preface 
This chapter provides a broad overview to my thesis including basic conception of 
multimorbidity, measures and prevalence of multimorbidity and the impact of 
multimorbidity on the health care needs and costs to the society. The evidence on 
what is known about multimorbidity and the impact on the working population is then 
reviewed. In order to situate the overall research aims of this thesis, Chapter 1 
reviews the key literature on how we identified the gaps step by step. More specific 
reviews of relevant literature are provided in Chapters 3 to 6. 
1.2 What is multimorbidity? 
Nowadays, more and more people with multiple coexisting health conditions is a 
major challenge facing the governments and health-care systems worldwide. This 
phenomenon includes not only those individuals with an index disease, which we are 
familiar with and known as comorbidity, but also those in whom multiple diseases co-
exist without an index disease, which was known as multimorbidity. However, these 
two terms require a clear distinction because of the inappropriately interchangeable 
use in the literature. 
1.2.1 Comorbidity & Multimorbidity  
Comorbidity and multimorbidity are the terms used most often when referring to the 
state of having multiple coexisting health conditions 1. “Comorbidity” is usually 
defined as “any distinct additional entity that has existed or may occur during the 
clinical course of a patient who has the index disease under study” 2. This definition 
differs from the newer concept of “multimorbidity”, in which several overlapping 
chronic health conditions are managed as equally-important to patient quality of life 
and outcomes 3. Nevertheless, much confusion still exists in the literature, where the 
terms of multimorbidity and comorbidity have been used interchangeably in studies 
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on multiple co-existing health conditions 1. It is thus important to clarify these 
concepts. 
The term of comorbidity was coined by Feinstein in 1970, while multimorbidity first 
appeared in the German literature, when published and translated by Wittig et al. in 
1976 4, and was then used broadly as a term in the medical literature 5. The definition 
of comorbidity emphasizes the unique role of one condition in a group. When there is 
a predominant health condition, triggered secondary health conditions which are 
caused by this predominant one, may occur during its clinical course 6. People can 
easily access healthcare services in this state, as the current health care system is 
predominantly designed to deliver care for single diseases, and patients can receive 
relevant treatments for secondary conditions as well during the treatment of the index 
condition. For instance, a person with diabetes who is affected by the associated 
retinopathy (comorbidity) can be g appropriately treated for retinopathy based on 
diabetes guidelines; however, a person with diabetes, cancer and cardiovascular 
disease (CVD) at the same time (multimorbidity) cannot obtain a completely effective 
treatment package for all of these three diseases. That is, a framework in which one 
health condition is considered central may not be useful when considering the optimal 
care and a health care system for multimorbid people, unless one health condition is 
dominant in terms of the well-being and health care of one person 6, 7.  
Figure 1-1. The differences between comorbidity and multimorbidity. 
*Suppose there are three health conditions: A, B and C. 
Therefore, this thesis focused on two critical components of multimorbidity that are 
distinct from “comorbidity”: “no index disease” and “simultaneous coexistence”. 
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1.2.2 Concerns about Multimorbidity  
Multimorbidity has drawn more concerns than comorbidity. The first concern pertains 
to the increasing global prevalence of multimorbidity.  
Studies on the prevalence of multimorbidity have been conducted globally and show 
that multimorbidity is far more prevalent than each single health condition alone 8, 9. 
Globally, more than 25% of people on average suffer from multimorbidity 7, 10, and 
this figure is expected to increase in the coming years 11. In the general population, 
the prevalence of multimorbidity has ranged from 13.1% to 71.8% across studies 12 
and, the boarder prevalence in the primary care setting ranged from 3.5% 13 to 98.5% 
14. For example, Schram et al. pooled data from seven various levels of databases to 
estimate the prevalence of multimorbidity, which was most prevalent in nursing 
homes (82%), followed by in the general practitioner registries (56%-66%), general 
population (56%-71%) and the hospital setting (22%) 15. In the Netherlands, Uijen et 
al. found that the prevalence of individuals with two or more chronic health 
conditions increased from 12.3% to 20.5% over two decades, from 1985-2005 16. In 
America, Ward et al. found that this prevalence increased from 21.8% in 2001 to 
25.5% in 2012 17, 18. Although the prevalence of multimorbidity varies depending on 
the population source as well as the definition and measure of multimorbidity, an 
increasing prevalence has been clearly observed 19.  
Moreover, as the number of health conditions included in the definition increases, the 
prevalence estimates of multimorbidity also increase 20. For example, Fortin et al. 
used a list of seven health conditions as well as an open list of conditions and found 
that compared with the estimates for the list of seven health conditions, the 
multimorbidity prevalence estimates for the younger age group based on the open list 
in the practice-based group were approximately 4.3 times and 2 times the estimates of 
the middle-age group 20. 
The second concern regarding multimorbidity is the higher consumption of resources.  
A higher number of multimorbid conditions has consistently been shown to be 
associated with a substantially greater share of resource consumption, including 
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inpatient services, specialized care, primary care, medications, and even personal time 
spent on health care, in numerous populations and settings worldwide 21-24. 
Approximately two-thirds of the total American health care spending is estimated to 
be devoted to persons with multimorbidity in the Medicare programme 25. 
Furthermore, approximately 58% of patients attending general practice in the United 
Kingdom have multimorbidity and account for roughly 78% of all consultations 25. In 
Australia, the median monthly time spent on health-related activities was 5-16 hours 
for those with multimorbidity, and patients with five or more conditions spent up to 5-
8 hours per day 24. 
The third concern is about the implications of multimorbidity for health care systems. 
As a global health challenge, multimorbidity has a significant impact on current 
health systems, given the higher associated health care needs 25. Challenges arise for 
all stakeholders. For people with multimorbidity themselves, they suffer from the 
effects of multiple illnesses without hope, and many prefer being treated holistically 
rather than as having a series of disparate diseases. This type of person-focussed 
approach 7 is likely to produce greater gains in self-management and in subsequent 
improved health and quality of life outcomes 7. However, health care providers 
struggle to meet the complex needs of people with multimorbidity and have a sense of 
powerlessness and frustration, as the guidelines and professional training are largely 
specific to single-diseases 26. Moreover, the effects of single diseases are not simply 
summed within individuals 21. For governments and society, they have substantial 
investments in caring for multimorbid conditions with far fewer gains. 
1.2.3 The absence of uniform way of defining multimorbidity  
Although multimorbidity has increasingly becoming the most prevalent “chronic 
condition” and not the exception 26, effectively and efficiently managing 
multimorbidity, appropriately allocating the related health resources, and improving 
quality of life remains an unrealized goal in routine care. A major obstacle to better 
understanding multimorbidity and providing cost-effective treatment is the lack of 
consensus regarding how to measure multimorbidity. 
 5 
 
At its simplest, multimorbidity is defined as the presence of multiple co-occurring 
chronic health conditions without an index disease in a given person 27. Based on this 
basic definition, four or more health conditions and 1,631 different criteria have been 
used in the medical literature to identify multimorbidity. Multimorbidity as been 
investigated within three general categories: i) the number of chronic health 
conditions (count-based method), ii) the cluster of chronic health conditions (cluster-
based method) 28, 29, and iii) questionnaire-based methods. The first one is generally 
used because of its user-friendly nature and lack of technical requirements, while the 
second definition is statistically complex; finally, the last definition requires a pre-
designed questionnaire that addresses “multimorbidity” in the first place. More details 
of the differences between these three methods are discussed in the following 
sections. 
Count methods 
Although the number-based count method is used widely, recent systematic reviews 
have raised some specific issues about this approach 12, 30. The cut-off value, which 
means the minimum number of co-existing chronic conditions one individual should 
have to determine the presence of multimorbidity, is the first issue 21. Different cut-off 
values have been used 14, 30-32. For example, Harrison et al. reported that in 
populations with a broader age scope, the two-condition cut-off approach was more 
appropriate, whereas the three-condition cut-off approach was more appropriate to 
elderly populations 31. Furthermore, the two-condition cut-off is recommended when a 
limited number of pre-specified chronic health conditions are included in the 
definition of multimorbidity, whereas the three-condition cut-off requires more 
chronic health conditions to be included 31. However, all cut-off values should be used 
with caution, particularly because the number of health conditions in the current 
studies varies, largely due to data availability; furthermore, the majority of papers did 
not provide clear reasons for the criteria of included health conditions 12, 30. Most 
commonly, they simply chose the health conditions with a high impact or high 
prevalence 30.  
Whether to group multiple health conditions affecting the same body organs into one 
category or to consider them individually is also controversial. For example, for 
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myocardial infarction and chronic ischaemic heart disease 30, the prevalence of 
multimorbidity would clearly be higher when they are considered two conditions 
rather than only one (CVD). The subsequent health outcomes measure would differ as 
well 33. Defining multimorbidity by organ systems may be helpful for reducing health 
care utilization, as different health conditions in the same organs could be treated by 
the same health professional.   
However, determining whether to group conditions depends on the number and the 
approach used to access health conditions in the pre-specified lists outlined in 
surveys. The lack of data regarding precise multimorbid conditions could result in 
difficulties capturing multimorbidity. More research is thus needed to better 
understand multimorbidity. 
Cluster-based methods 
The count methods, which results in all the possible clusters of health conditions, 
prompted the development of cluster-based methods to identify specific clusters of 
multimorbidity 34-36. The main ways by which multiple chronic health conditions can 
be clustered in an individual are by chance, by selection bias and by causal 
associations 6. Two health conditions can coexist simply by chance. Assuming that 
there is a population in which 4% have type-2 diabetes and 5% have eczema, by 
chance alone, 0.2% (=4%*5%) of this population would have both conditions 6. 
Selection bias occurs due to study design. For example, Berkson et al. observed a 
higher prevalence of clusters of conditions in persons seeking care than in the general 
population 37, as those accessing health care were more likely to acquire additional 
diagnoses. Using community samples or population-based data rather than including 
only patients is an effective approach to preventing this type of bias. Finally, causal 
associations are more likely to refer to “comorbidity”, which is discussed in section 
1.2.1 and is not within the scope of multimorbidity and thus will not be discussed 
further. 
The statistical methods used to capture clusters of conditions have also been explored. 
For example, Cornell et al. used hierarchical clustering analysis 38, Schafer et al. and 
Prados-Torres et al. performed factor analysis 34, 39, and Islam et al. adopted two other 
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approaches: principal component analysis and latent class analysis 36. These studies 
showed that identifying common clusters of co-occurring health conditions could 
improve clinician understanding and, to some extent, help develop better practice 
guidelines for multimorbidity 24, 36, 40, 41. Some clusters are particularly problematic for 
both patients and clinicians. For example, clusters of respiratory/cardiac body system 
morbidities have a strong synergistic negative interaction 42. The cluster of 
musculoskeletal health conditions with vascular or upper gastrointestinal symptoms 
may result in the use of non-steroidal anti-inflammatory agents, increasing the 
mortality of the other two conditions, particularly in the elderly 43. The guides for 
single conditions rarely have taken these issues into account. 
Moreover, big differences in the nature of multimorbidity in the different study 
settings have been identified. Clusters of heart diseases/hypertension/osteoarthritis are 
predominant in population-based settings, clusters of heart health conditions are most 
prevalent in the hospital settings, whereas hypertension/diabetes/ 
osteoarthritis/obesity/lipid metabolism disorders are predominant in the primary 
healthcare settings. Finally, in the nursing home setting, clusters of dementia, 
hypertension, and stroke were predominant 15.  
Questionnaire-based methods 
In addition to the two popular methods mentioned above, researchers have also tried 
to develop tools to better understand and identify multimorbidity. Comorbidity can 
occur separately from multimorbidity, we now know that these two conditions should 
be distinguished from each other. However, given their connection, some tools 
referring to comorbidity are often used in attempts to access multimorbidity, such as 
the Cumulative Illness Rating Scale (CIRS) 14, 44-46 and the Johns Hopkins Adjusted 
Clinical Group case-mix system (ACGs) 47, 48. The advantage of these tools is that 
they account for the “severity” of conditions 12. One disadvantage is the limited space 
on questionnaires and the reduced response rate due to the additional burden of 
completing questionnaires 31. Additionally, the original survey designs require 
additional mapping of diagnoses from the classification system in which the health 
records were documented 31. That is, it is impossible to access these tools if the survey 
does not incorporate them, particularly if multimorbidity is not currently included in 
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the regular content of national health surveys. Even in those few available surveys, 
the target populations are specific, such as in the Bettering the Evaluation and Care of 
Health (BEACH) programme, which focused on primary health care patients.  
Other than the direct quantitative methods used to identify multimorbidity, some 
studies have also proposed proxy measures in primary care, such as the number of 
prescribed drugs 49. These researchers have suggested that this measure could be a 
potential simple predictor of multimorbidity 50. However, there is insufficient 
evidence and the systematic reviews on existing multimorbidity-related methods 
emphasize the heterogeneity in the current studies 30, 51. The selection of different 
methods depends on the type of available data and which is most appropriate 
according to each study’s outcome of interest. Combining different methods in the 
same study can lead to a better understanding of multimorbidity 51.  
A list of included health conditions  
The lists of health conditions included in different studies on multimorbidity vary 
greatly. Some authors have limited their investigations to a short list of conditions of 
particular relevance to their setting. Others have included all possible health 
conditions experienced by the individuals. Not surprisingly, the more health 
conditions that are included, the higher the probability of detecting multimorbidity.  
According to the World Health Organization (WHO), multimorbidity is determined 
by non-communicable diseases (NCDs), which are not passed from person to person 
52. Fortin et al. suggested that the most prevalent chronic health conditions with a high 
impact or burden on a given population should be included in these definitions. Other 
than non-communicable chronic conditions, chronic but communicable conditions 
have also been included in some previous studies, including human 
immunodeficiency virus (HIV) 53 and hepatitis 54. Moreover, acute conditions are 
unlikely to be considered in multimorbidity studies, as they may only temporarily 
influence health status 31 and may not be relevant to long-term health care planning. 
In summary, multimorbidity is a state experienced by multimorbid people rather than 
a medical diagnosis. Although a detailed list would be impossible for all communities, 
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a list of the most prevalent chronic health conditions with a high impact or burden in a 
given population would provide a good compromise 12. Moreover, for the purposes of 
research and reporting, we should agree on a definition that is measurable, 
comparable and conceptually sound, as the number and types of health conditions 
selected and their grouping greatly affect any related estimates.  
Different definitions, however, may produce different associations of multimorbidity 
with health outcomes; these definitions were adopted in isolation before and are 
hardly comparable due to the variance in settings between the different studies. 
Therefore, a rigorous evaluation of methods designed to capture variations in the 
different definitions of multimorbidity and their effects on health status at the 
population-level is warranted, as the lack of studies examining the association of 
multimorbidity with health status using different definitions of multimorbidity hinders 
comparisons and further explorations of multimorbidity-related studies. This is the 
major challenge we are facing and the first gap we identified in this thesis.  
1.3 Multimorbidity & health-related outcomes 
Despite the absence of a uniform method of defining multimorbidity, qualitative work 
has established that in general, the state of “multimorbidity” is associated with poorer 
outcomes for multimorbid people. The following sections provide more details about 
these associations.  
1.3.1 Multimorbidity & health-related quality of life  
Health-related quality of life (HRQoL) is a subjective outcome measure with a 
multidimensional perspective that is increasingly being used to capture the holistic 
health status of people with chronic diseases 55. Although previous studies have 
shown that HRQoL scores generally decrease with an increasing number of co-
occurring chronic health conditions 42, 56, 57, some specific clusters of multimorbidity 
are more strongly associated with poor HRQoL than others, such as clusters between 
mental and physical conditions 58. The combined associations of co-occurring chronic 
health conditions with HRQoL have received some attention 59-62, and knowledge of 
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clusters that potentially have a greater impact on HRQoL may help map the 
population burden of multimorbidity and can inform health planning.  
In the literature, there are three main approaches to identifying clusters of 
multimorbidity: the most prevalent clusters in a given population, clusters of physical 
and mental disorders and statistical cluster-based methods. The most prevalent 
clusters in a given population are not necessarily the clusters with the greatest burden. 
For example, the cluster of diabetes and acid peptic illness was the most costly pair of 
chronic diseases (excluding psychosis) in an American Medicaid sample but was only 
present in 30/41,159 people; by contrast, the cluster of hypertension and diabetes was 
approximately 10 times (310/41,159) as prevalent as the cluster of diabetes and acid 
peptic illness but was the third least expensive 63. Clusters of physical and mental 
disorders are normally of interest in studies focusing on mental disorders, as the 
clustering may produce a significantly different association of physical disorders with 
health outcomes. To capture common clusters of multimorbidity with statistical 
methods, researchers have used cluster-based methods, such as cluster analysis 64, 65, 
factor analysis 34, 66 and hierarchical analysis 38. The different methods use different 
mechanisms to identify clusters, such as, cluster analysis use distance measures, 
whereas factor analysis and principal component analysis use correlations. In most 
studies, investigators have used only a simple list of health conditions to detect the 
clusters in patients, and this list provides very incomplete information that is quite 
narrow in scope for presenting the association between multimorbidity and HRQoL. 
However, little is known about the associations between multimorbidity and HRQoL 
using various methods of defining multimorbidity, as there is no consensus definition.  
1.3.2 Multimorbidity & healthcare service utilization 
People with multimorbidity have complex health care needs compared to those with a 
single health condition, and they are at risk of insufficient care and adverse treatment 
effects, such as adverse drug events caused by polypharmacy 67. Therefore, meeting 
the health needs of people with multimorbidity and determining how they use health 
care is an integral part of routine general practice.  
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Many studies have found that healthcare service utilization significantly increases 
with each additional condition 67, yet the rate of increase declines per additional 
condition 68. People with multimorbidity have higher overall health service utilization 
than people with a single condition, including more frequent and longer 
hospitalizations, readmissions, and physician visits 25, 26, 67, 69-71. However, healthcare 
utilization is multifactorial and potentially subject to measurement error 72. The more 
health conditions a person experiences, the higher the risk is of measurement error. As 
health care is still predominantly delivered according to individual diseases 73, it is 
useful to understand health care utilization patterns for diseases when they are 
multimorbid versus when they occur individually. Additionally, most studies have 
focused on higher risk populations, such as patients who frequently use healthcare 
services and the elderly, who are more likely to present with multimorbidity 74.  
Understanding how people use health services for single diseases in the context of 
multimorbidity is essential to gaining insight into their healthcare demands and reduce 
the consequences of multimorbidity. Increasing health care utilization has been 
noticed. For example, in Australia, the average number of GP visits has increased 
from 4.5 per person in 1987–1988 to 5.6 per person in 2012–2013 75. However, we 
were unable to identify any studies that reported the associations between 
multimorbidity and disease-specific healthcare utilization, which referred to a series 
of single-disease evaluations. 
1.3.3 Multimorbidity & the related economic burden 
Regardless of the specific definition of multimorbidity adopted, the prevalence of 
multimorbidity ranges from 13.1% to 71.8% in the general population 12. 
Additionally, a growing body of evidence has indicated an increasing prevalence of 
multimorbidity 11. In the Netherlands, Uijen and van de Lisdonk found that the 
prevalence of people with two or more chronic health conditions increased from 
12.3% to 20.5% over two decades, from 1985-2005 16. In the United States, Ward 
found that multimorbidity increased in prevalence from 21.8% in 2001 to 25.5% in 
2012 17, 18. 
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Although multimorbidity is not a specific disease, strictly speaking, it has increasingly 
become one of the most problematic “chronic health conditions” 76, not only because 
of the prevalence but also because of its far-reaching consequences. For example, 
multimorbidity can have a drastic and lifetime impact on the lives of those affected, as 
it is unlikely to be cured. Additionally, compared to single health conditions, 
multimorbidity has been related to poorer HRQoL 77, higher health service utilization 
70, and negative occupational consequences 78, such as productivity loss due to 
presenteeism (e.g., ‘continuing to work while sick’) and absenteeism. Moreover, 
healthcare resource consumption is expected to increase not only because of the 
accumulation of chronic health conditions but also because of the interactions and 
synergies between health conditions within an individual 79. Given the concurrent 
changes in epidemiology, the use of resources and morbidity-related costs of 
multimorbid conditions are likely to have undergone enormous changes as well.  
Cost-of-illness (COI) studies have provided valuable information for modelling the 
costs of chronic conditions and have been performed to evaluate the costs of 
multimorbidity. However, there is no summary evidence of the economic burden of 
multimorbidity, especially given the lack of a uniform definition and measurement 
method. Therefore, a systematic review of studies on the costs of multimorbidity that 
analyses the different methods used, summarizes the findings on the economic impact 
of multimorbidity and evaluates the quality of the included COI studies, particularly 
examining how the costs differ with various definitions of multimorbidity, is urgently 
needed. 
1.4 Managing multimorbidity 
As described above, there is well-established evidence highlighting the complexity 
associated with multimorbidity 28, 80, 81. Compared with those with single health 
conditions, people with multimorbidity are more likely to die prematurely, be 
admitted and stay longer in the hospital 82, 83. They have poorer HRQoL, have loss of 
physical functioning and are more likely to experience depression and to receive 
multiple drugs with subsequent difficulties with adherence 84, 85. The impact of 
socioeconomic deprivation is also evident, as onset of multimorbidity occurs 10-15 
years earlier in people living in the most deprived areas compared with those living in 
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the least deprived areas 9. However, the delivery of health care that is predominantly 
built around single health conditions may not be appropriate for the people with 
complex health problems and overlapping healthcare services 14, 67. 
From a more pragmatic perspective, few studies to date have investigated the effect of 
multimorbidity on processes of care and what constitutes “best care” for these 
patients. Although a systematic review on this topic found that the current 
interventions have had mixed effects 32. The continuity of health care for the people 
with long-term health conditions may lead to lower health care costs, fewer health 
care service visits and complications 86. Moreover, because of the high prevalent long-
term health conditions, the morbidity and mortality could be reduced substantially 
with a national-level primary healthcare pathway 87. Improving the awareness of 
people’s understanding of multimorbidity may have implications for the provision of 
care and for the design of interventions for multimorbid people with complex needs 
88; however, whether these management approaches suit the situation of 
multimorbidity remains quite unclear. 
There is a significant gap in evidence-based recommendations for people with 
multimorbidity 89, as the current evidence highlights the lack of a clear theoretical 
framework that currently guides interventions for multimorbidity 32.  
1.5 Multimorbidity in the working population 
Another major challenge to the improved understanding and management of 
multimorbidity is the rapid demographic and epidemiological changes that have 
occurred globally 90, 91. Although the population of people aged 60 years and over will 
increase from 600 million in 2000 to 2 billion in 2050 92, living longer does not 
necessarily mean living healthier 91. Much of the burden of death and illness occurring 
in old age is attributable to chronic conditions, which require long-term care 93. 
Nevertheless, one issue is that people cannot afford the costs and have to stay in the 
workforce to support long-term care, even if they have already reached the retirement 
age. According to recent Australian data, 23% of the working population aged 40 
years and over expected to continue working until they were 70 years old, and this 
proportion was only 8% ten years ago 94. Therefore, a challenge with particular 
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relevance for understanding the burden of multimorbidity is the extended working life 
for many people. 
The health of the workforce is central to a country’s economic well-being. With 
63.4% of all adults worldwide being in the workforce 95, ageing coupled with 
increasing the national retirement age 94, 96 has led to more employees with 
multimorbidity in the workforce 97. Although the prevalence is naturally higher 
among people aged 65 years and over 26, 67, around half of the multimorbid population 
is younger than 65 years 21, 81, 98. All of the figures shown here illustrate that 
multimorbidity is not only a problem among older adults but is increasingly affecting 
younger adults, given the sociodemographic and health changes in the population. 
This is likely to produce notable effects on a particular segment of the population – 
working adults. 
The multimorbid working population is of concern not only because of their health 
care costs but also because of productivity losses, which are much greater and only 
occur in the working environment 86. To date, employers have devoted inadequate 
attention to health-related productivity loss, as they have only attempted to understand 
medical and pharmacy spending due to poor employees health 99. The ways in which 
employers control or reduce the costs may result in worse clinical health outcomes 
and facilitate productivity loss and include shifting costs to employees and limiting 
insurance coverage 100, 101. The cost of lost productivity from employees who are 
absent due to sickness (also known as absenteeism) and from present employees who 
cannot fully engage in work due to illness (also known as presenteeism) is substantial 
102-104. The costs of presenteeism itself is two to three times greater than direct health 
care costs 102.  
This situation has become more complex due to co-existing health conditions 105. A 
positive association between the number of chronic health conditions and work 
performance has been observed. For example, in a multi-employer study that 
combined claims data from 1,134,281 American, Loeppke et al. found that 
productivity loss increased as the number of health conditions increased and was 1.3 
times greater than the costs of direct health care 99. In another study, Lenneman et al. 
adopted a list of five chronic health conditions to assess their relative contribution to 
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rates of productivity impairment and concluded that there was significant growth in 
impairment as the number of health conditions increased 106. Additionally, studies 
have focused on the impact of a specific combination of chronic health conditions on 
lost productivity, but they emphasized the role of mental disorders. For example, 
Kessler et al. conducted a study using nationally representative data from the United 
States and found that comorbid mental and physical disorders could result in more 
role impairment than physical disorders without mental disorders 107.   
Very little is known about the impact of multimorbidity on the working population 
and the type of support people need to continue working while also managing 
multimorbidity. This lack of knowledge represented the second gap that we aimed to 
address though this thesis. This important gap in understanding was recently 
recognized by the National Institute for Health Care Excellence (NICE) in the UK 
though a project that aimed to develop a guide for employers and employees on 
effective and cost-effective approaches to promote and protect the health of workers 
with long-term conditions and to effectively manage sickness absence associated with 
these conditions 108. However, this gap has not been filled thus far. 
1.6 The Australian context 
This thesis was based on data from the Australian population, and thus the 
multimorbidity-related context in Australia will be introduced.  
Australia faces significant fiscal pressure and policy challenges resulting from the 
increasing prevalence of multimorbidity and the rising economic burden. There have 
been a number of effects implemented in response to this situation. However, reports 
from the Australian Institute of Health and Welfare (AIHW) and the Australian 
Bureau of Statistics (ABS) recommend that further change is needed to ensure the 
future development of the Australian health system. To establish and maintain a 
globally competitive and healthy population, all stakeholders such as clinics, policy 
makers and people with multimorbidity need to better understand the health-related 
issues caused by multimorbidity. This is particularly important for the working 
population, as the Australian workforce is rapidly changing.  
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In March 2016, ABS released a report “6238.0-Retirement and Retirement 
Intentions”. This publication presented information about the retirement status and 
intentions of Australians aged 45 years and over who had worked at least two weeks 
and shown more Australians than ever (4 times of the number in 10 years ago) would 
not retire until 70 years old. A postponed retirement has led to the increased pressure 
on health care and often been associated with increased health conditions because of 
aging. To establish and maintain a healthy and productive workforce, a better 
understanding of the health issues affecting the Australian workforce is needed. This 
is particularly important for multimorbidity, which predominantly leads to worse 
health-related outcomes. However, multimorbidity in the Australian working 
population has not been well studied. 
The national health priorities used in the Australian national health surveys conducted 
by ABS were determined according to the conditions that were prevalent and highly 
costly in the Australian community. The health conditions used to capture the 
nationally representative estimates of multimorbidity in this thesis were consistent 
with the identified Australian national health priority areas. However, the survey was 
not initially designed to measure multimorbidity, and thus more research is needed to 
better meet the exact data collection requirements to address the health-related gaps 
due to multimorbidity. The third gap identified in this thesis was whether our current 
large national prevalence surveys fully measure multimorbidity. 
1.7 The need for further research  
Studies in the field of multimorbidity research should use more consistent definitions 
of multimorbidity. Additionally, there is a need for more evidence on multimorbidity 
and HRQoL using different definitions of multimorbidity based on a nationally 
representative population. Samples at high risk, such as the elderly and those in 
primary health care, have been accessed in previous studies, yet there is a lack of 
adequate evidence in the general population, particularly the relatively healthy, but 
especially in an important group - the working population. Given the considerable 
evidence on co-morbid physical and mental disorders with an index mental disorder 
and of the high effects of mental disorders on reducing health outcomes, more studies 
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are needed that explore the relationship between co-occurring physical and mental 
disorders without an index disease and a range of health outcomes.  
1.8 How this thesis addresses the identified gaps 
In sum, the first identified gap was that “no studies have examined the association of 
multimorbidity with health status using different definitions of multimorbidity”; the 
second identified gap was the lack of knowledge regarding whether “multimorbidity 
is an issue in the Australian workforce”. Therefore, to address the identified gaps, the 
primary aim of this thesis was to address the gaps in knowledge regarding the 
associations of multimorbidity with quality of life, health care service use, 
productivity losses and the related financial burdens, particularly in the working 
population.  
These gaps in knowledge were addressed using three different large samples of 
Australians. These samples were from the National Survey of Mental Health and 
Wellbeing (NSMHW), Confidentialised Unit Record Files, 2007; the National Health 
Survey (NHS) 2011-13 and partnering Healthy@Work 2013. The first two datasets 
are representative of the Australian population and therefore allowed us to answer the 
question of whether our current large national prevalence surveys are able to 
appropriately measure multimorbidity and whether they need improvement. This was 
the third gap we identified and the secondary aim of the thesis we wanted to achieve. 
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Chapter 2 
 
Chapter 2. Methods 
This chapter provides an overview of the data sources used in analyses for Chapter 3-
5, and illustrates some of the challenges in investigating multimorbidity in 
community-based (non-clinical) populations.  
2.1 The National Survey of Mental Health and Wellbeing 2007-
Chapter 3 
This data source was used in Chapter 3. Given the confidential natural, 
NSMHWB2007 provided the basic Confidentialised Unit Record File (CURF) on 
physical media (a CD-ROM) and required me to register as an approved CURF user. 
Even the purpose of this survey was to obtain information on selected lifetime and 
one-year mental disorders, it also collected information on demographic and socio-
economic characteristics, the HRQoL score and a range of health conditions of 
concern to the Australian population 1. This sample therefore considered appropriate 
to address our study aim, examining the performance of the count-based and cluster-
based definitions of multimorbidity on the sociodemographic profile and HRQoL in a 
general population. Moreover, this survey is still the most current national prevalence 
survey of mental disorders using a diagnostic interview that Australia has so far. All 
technical details from the survey have been reported from the following documents: 
National Survey of Mental Health and Wellbeing, Confidentialised Unit Record Files 
Technical Manual-4329.0 2 and National Survey of Mental Health and Wellbeing: 
Users' Guide, 2007-4327.0 1. 
2.1.1 Study Design 
Respondents living in private dwellings included in the survey were selected 
randomly using a stratified, multistage area sample 2. This made the younger (16-24 
years) and older (65-85 years) age groups have a higher chance of selection for 
interview than their other members in the household from different age group. To 
ensure the reliability of estimates derived using the NSMHWB, person and household 
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weights were developed separately 2. The first step in generating weights was 
assigning the initial inverse of the probability (weight) of being selected from the 
survey. The second step was generating the differential probabilities of selection by 
age to consider the oversampling of younger and older age groups. The last step was 
calibrating person and household weights separately to ensure the estimates 
conformed to the estimated distributions of the population rather than to the 
distribution within the sample itself. This process is referred to as 'benchmarking' and 
can reduce sampling error and the non-response bias. Moreover, in ABS household 
surveys, the person and household weights were calibrated to population by state, part 
of state, age and sex, to project the in-scope persons except for those living in the 
Australian very remote areas, at 31st October 2007 2. 
2.1.2 Data Collection 
Trained interviewers conducted face-to-face interviews at selected private dwellings. 
The average length of the interview was 90 minutes 1. General characteristics of the 
household and all the included members, including gender, age, and the relationships 
between household members were collected from one household member aged more 
than 16 years on the first face-to-face contact. The same interviewee answered 
questions about household income and housing tenure, on behalf of other household 
members. This information was used to identify in-scope individuals who were of the 
survey and one person aged 16-85 years was randomly selected to be included in the 
next stage of the survey.  
2.1.3 Survey Response 
Initially 17,352 private dwellings were selected for data collection. This was reduced 
to 14,805 due to no in-scope resident or the dwellings were vacant, under construction 
or derelict. Of the eligible dwellings, 40% did not respond fully including 61% full 
refusals, 27% which did not complete the main questionnaire, and 12% which did not 
provide enough information or cannot be contacted. Of the remaining eligible 
dwellings, there were 8,841 fully responding households, representing a lower than 
expected survey response rate of 60%, which can result in a biased sample and create 
non-sampling error. Therefore, extensive non-response analyses, including 
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comparison of population characteristics in the NSMHWB2007 with other data 
sources and a small sample Non-Response Follow-Up Study (NRFUS), were 
conducted to evaluate the reliability of the survey estimates. No explicit adjustment, 
however, was made to the weighting strategy because of the negligible impact of 
extensive analyses on survey estimates 2. 
2.1.4 Measuring Multimorbidity 
To identify multimorbidity, a pre-specified list of chronic physical conditions and 
mental disorders was used. Chronic physical conditions were obtained via the chronic 
conditions module. This module contained a standard checklist to obtain information 
on the prevalence and recency of Australian National Health Priority Area (NHPA) 
chronic physical conditions 2. The information was self-reported by the respondent. 
Even not verified by a medical practitioner, this is a commonly approach the large 
prevalence population health surveys adopting to measure the prevalence of chronic 
conditions worldwide 3-6. 
These physical conditions included asthma, cancer, stroke (or the effects of a stroke), 
gout, rheumatism or arthritis, diabetes or high blood sugar levels, and any other heart 
or circulatory condition. If a respondent had ever been told by a doctor or nurse that 
they had one (or more) of these conditions, they were then asked i) if they had 
received any treatment for the condition/s in the 12 months prior to interview, ii) if 
their condition/s had lasted for six months or more, and iii) their age the first time 
they had the condition/s 1. 
In the NSMHWB, the included mental disorders had to meet three criteria: i) an 
expected prevalence of more than 1%, based on the diagnosis of a lifetime disorder 
with or without symptoms in the 12 months prior to interview; ii) they were able to be 
diagnosed through the WMH-CIDI 3.0; and iii) they were likely to be identified 
through a household survey. So the selected mental disorders in this survey were 
diagnostic and considered to have the highest rates of prevalence in the population 
and that are able to be identified in an interviewer-based survey.  
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As a result, Chapter 3, which used NSMHWB data, focused on individuals with 
multimorbidity being defined from a pre-specified list of chronic conditions. They 
were asthma, cancer, stroke, heart or circulatory conditions (CVD), gout, rheumatism 
or arthritis, diabetes or high sugar levels, major depressive disorder (MDD) and 
anxiety disorder (including agoraphobia, with or without panic disorder, generalized 
anxiety disorder (GAD) and social phobia).  
2.1.5 Measuring Health-related Quality-of-Life 
The Australian-developed Assessment of Quality-of-Life 4D (AQoL-4D) instrument 
was used to measure HRQoL. The AQoL-4D was brief, using four dimensions, 
independent living, relationships, mental health and senses) and 12 items measured 
how a person's health impacted on their self-care, household tasks, mobility, 
relationships, isolation, family role, sleeping habits, feelings in general, level of pain 
or discomfort, and seeing, hearing and communication 7. As a generic instrument, the 
weighted scoring of AQoL-4D questionnaire is computed to provide dimension scores 
and an overall index of health state utility and ranged from −0.04 to 1 8. A score of 
1.00 indicates the best quality of life equal to perfect health, 0.00 indicates quality of 
life equal to death, and negative values (0 to −0.04) indicates quality of life worse 
than death 9. 
2.1.6 Study Sample 
The NSMHWB provided a data set consisting of sample of 8,841 respondents aged 16 
to 85 years of age and living in private dwellings 2. No missing data strategy was 
needed because of the 2.6% low rate of missing data. The final data set in the 
regression models consisted of 8,820 respondents. 
2.1.7 Standard error calculation 
Because of the NSMHWB’s complex survey design, the standard errors presented in 
Chapter 3 were calculated and adjusted for non-response to remove over- or under-
representation of certain demographics 10 using Jack knife delete-1 replication 
methods 11, behind which the theory 2 is that, the sampling variance between repeated 
28 
 
samples could be obtained by repeatedly taking random, unbiased sub-samples after 
accounting for the smaller sample size. Jack-knife replicates, particularly are 
generated by removing one population-sampling unit (PSU) from the dataset at a time 
and weighting up the other PSUs from the same stratum to adjust for this removal. 
Therefore, each replicate provides an unbiased estimate of the population mean, and 
the variance between the replicate means give an estimate of the in-scope sampling 
variance.  
2.1.8 Ethics statement  
Ethics approval was not required for the study described in Chapters 3 as the used 
data that were non-identifiable and conducted in accordance with ABS data release 
policies.  
2.2 The 2011-12 National Health Survey-Chapter 4 
The data source used in Chapter 4 was derived from NHS which is one of Australia’s 
largest health surveys with the health surveillance purpose, conducted by the ABS 
every three to six years since 1989. It collected information from a range of chronic 
health conditions (e.g. cancer) and health care service use (e.g. times of visiting 
general practitioners) for each collected chronic health conditions, demographic and 
socio-economic characteristics as well as working status of the respondents. 
Meanwhile, using the weighting strategy, it produced the generalisable estimates of 
national workforce rather than the particular groups, such as the small-size company 
or government employees. The data we used was undertaken in March 2011- March 
2012 which was the newest one at the time this study was conducted, and therefore 
considered appropriate to address the study aim, understanding the patterns of 
healthcare service utilization in employees with multimorbidity. All technical details 
from the survey have been reported from the document, Australian Health Survey: 
Users' Guide, 2011-13, 4363.0.55.001 6. 
2.2.1 Study Design 
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The 2011-12 NHS collected information suing face-to-face interviews from usual 
residents of private dwellings in urban and rural areas of Australia, and covered 
approximately 97% of the Australian population 6. Foreigners intending to stay in 
Australia for 12 months or more were also in scope. Dwellings included in this survey 
were selected in each state and territory using a stratified multistage area sample. This 
area-based selection ensured that the selected sample were representative of the 
people within the geographic scope of the survey. Similar as in the NSMHWB 2007, 
separate person and household weights were calculated in the NHS to infer results for 
the total in-scope Australian population.    
Unlike the NSMHWB, the NHS CURF was not provided on physical media but was 
rather accessed via an online analysis tool. The 2011-12 NHS was the component of 
the Australian Health Survey in the online form of a TableBuilder dataset and an 
Expanded CURF, which allows the approved users to analyse the dataset via the 
Remote Access Data Laboratory (RADL) 6, 12. The Expanded CURF contains unit 
records relating to all of the survey respondents. To protect the confidentiality of 
respondents and minimise the risk of spontaneous recognition, some variables were 
omitted and some variables had the response categories reduced 6. The effects of the 
changes made on data for analysis purposes are considered negligible 6.  
2.2.2 Data Collection 
Trained ABS interviewers collected information using CAI instrument. General 
characteristics of the household such as the number of usual residents of the dwelling 
residents, their basic demographic characteristics, and the relationships between those 
people, were obtained from any responsible adult member of a household. In a 
household, at least one adult and one child (where applicable) were selected for 
inclusion. No further information was asked from that household if the dwelling 
contained only usual residents aged under 18 years 6. 
2.2.3 Survey Response 
21,108 private dwellings were chosen in the sample for the NHS. In cases where a 
respondent refused to do the survey or there was non-contact due to absence at the 
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time of the visit, a follow-up letter was sent to that household. A second visit was 
made to explain the aims and importance of the survey, and to answer any particular 
concerns of respondents. No further contact was made if they refused to participate at 
the second visit. Except in the Northern Territory where an additional 53 households 
were obtained to the sample between December 2011 and March 2012, people missed 
due to non-contact or refusal were not replaced. However, the number of the actual 
dwellings reduced to 18,355 due to non-response. Ultimately, there were 15,565 fully 
or adequately responding households, representing a response rate of 84.8%. No 
explicit non-response adjustment was made to the weighting strategy in NHS, as the 
effect of the investigated non-response adjustments to the estimates was negligible 6. 
2.2.4 Measuring Multimorbidity 
A pre-specified list of current and long-term conditions was used to identify 
multimorbidity. Respondents were asked whether they had been diagnosed with any 
of these conditions, whether these conditions were current at the time of the survey, 
which conditions had lasted at least six months, and which they expected to last for at 
least six months. All the reported conditions were coded into a single list, which was 
initially developed by the Family Medicine Research Centre at the University of 
Sydney, in consultation with the ABS 6. Then it was developed by the ABS based on 
mapping the International Statistical Classification of Diseases and Related Health 
Problems 10th Revision (ICD10) provided by the Family Medicine Research Centre 
for NHS. The chronic health conditions used in NHS 2011-12, and used to identify 
multimorbidity in Chapter 4, were kidney disease, heart and circulatory conditions 
diabetes mellitus, asthma, cancer, arthritis, osteoporosis and mental health. With the 
exception of kidney disease, all the other conditions listed are NHPA conditions, 
defined as of great importance in health policy planning and were specifically asked 
in individual modules to ensure high-quality detailed results for these conditions. As 
the interest of this study was disease-specific HSU, the non-multimorbidity group 
would include those with two chronic health conditions when using three cut-off 
count method to define multimorbidity, which means the disease-specific HSU may 
be affected by the co-existing health condition. Therefore, we adopted two cut-off 
rather than three here. 
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2.2.5 Measuring Health Care Service Utilization 
To estimate health care service utilization of the included health conditions, the NHS 
asked the respondents about the number of times they had seen a GP, specialist etc. 
These questions were only asked once for each health condition group. That meant 
when a respondent had two or more health conditions, these HSU questions would 
refer to all the conditions this respondent having in each question. This approach, 
therefore, restricted the calculation of total HSU for each respondent due to 
overlapping.  
For each condition group that respondents reported having, they were asked whether 
they had taken any of the actions from a pre-specified action-list (e.g. visited a GP, 
visited a clinic as an outpatient) in the last 2 weeks. If respondents had not visited a 
GP in the last 2 weeks, they were asked whether they had visited a GP in the last 12 
months, then reported the number of times they had visited a GP during that time. 
Similarly, respondents who had not consulted a specialist in the last 2 weeks were 
asked whether they had done so in the last 12 months and again asked to report how 
many times they had done so. Only the number of GP and specialist visits in the past 
12 months were reported in the NHS 2011-12.  
2.2.6 Study Sample 
The employment related information was collected from individuals aged at least 15 
years using a short-form version of the questions used in the ABS Monthly Labour 
Force Survey 6, 13. People were assigned to three groups including employed, 
unemployed and not in the labour force referring to “whether the person had a job in 
the week prior to interview”, “whether those who did not have a job were actively 
seeking work”, and “whether those actively seeking work were available to start 
work”. “Employed” respondents were those reporting that in the previous week they 
had worked in a job including those had a job but were absent from work during that 
time. Exclusions were those who usually had no more than one hour work time per 
week, had unpaid volunteer work arrangements, were away from work due to workers 
compensation, and were not, or did not know if, they were returning to work for their 
employer or not. 
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2.2.7 Standard error calculation 
Similar as in the NSMHWB, the NHS presented standard errors, which indicates the 
extent to which an estimate might have varied because only a sample of dwellings 
was included, due to the complex survey design employed. 
2.2.8 Ethics statement  
Ethics approval was not required for the study described in Chapters 4 either as the 
used data that were non-identifiable and conducted in accordance with ABS data 
release policies.  
2.3 The 2013 partnering Healthy@Work (pH@W)-Chapter 5 
This data source made available for study in Chapters 5 though the pH@W project, 
which was led by the University of Tasmania in partnership with the Tasmanian State 
Service (TSS) and funded by the National Health and Medical Research Council 
(NHMRC). The survey collected information from the employees aged 18 years and 
over on presenteeism, absenteeism, the presence of chronic health conditions as well 
as demographic and socio-economic characteristics. There was no national prevalence 
survey collecting both multimorbidity and the measures of absenteeism and 
presenteeism at one dataset, so even not at the national-level, this data source enabled 
exploration of the extent to which the lost productivity time is affected by 
multimorbidity which is a concern in the Australian working population. A large 
employed sample representative of its source population, however, is required as the 
next best source of evidence in this area. 
2.3.1 Study Design 
Healthy@Work was a health promotion program designed by the TSS and made 
available to its entire workforce. It had an organisational-level, settings-based 
approach to promoting health through the workplace, and aimed to support employee 
health behaviour change through the provision of workplace health promotion 
activities. Well-tested and commonly used population health questionnaires were used 
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where available. The pH@W data were collected in 2010 and 2013 using a repeated 
cross-sectional design 14-19. Repeated cross-sectional analyses are useful for providing 
a snapshot of the key health and work factors for the broader population. They were 
also deemed appropriate for evaluating large-scale program targeted at an entire 
defined population. Further, there is evidence of cohort and cross-sectional analyses 
achieving comparable estimates 20. There were only approximately 500 same 
participants responding to both of the surveys, so the primary data used in this study 
was the 2013 survey of TSS employees supplemented with some demographic and 
employment-related information sourced from the TSS human resources 
administrative database.  
2.3.2 Data Collection 
The sampling frame was all employees of the TSS. Each employee was assigned a 
unique code and assigned to a strata which processed by government 
agency/department, employment condition (full-time or part-time), and employment 
category (permanent or fixed-term/casual contracts). Using unique code based on the 
TSS employees ID numbers, employees invited to participate were selected by 
random sampling within each stratum. The information sheet, consent form and 
survey instrument were mailed by a commercial mailing company to either a work or 
home address of each randomly sample employee inviting them to participate in the 
survey. The completed survey forms were returned directly in reply-paid envelopes to 
the researchers in Menzies Institute for Medical Research, University of Tasmania. 
Oversampling was performed for a number of reasons. First, in very small agencies 
there was a risk that data from a limited number of respondents could be identifiable 
if results were to be reported at an agency level. Second, sufficient respondent 
numbers were needed from each agency to fulfil reporting obligations to the TSS. 
Third, this increased the numbers available for appropriate weighting and analysis in 
each agency and work characteristic stratum.  
The 2013 survey data were linked with an extract of TSS human resources 
administrative data. Each sampled employee was assigned an additional unique 
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pH@W survey ID. The TSS administrative data were matched to survey respondents 
using these corresponding IDs. 
2.3.3 Survey Response 
Survey response rates to workplace questionnaires are characteristically moderate to 
low 21, 22. Nevertheless, previous research has demonstrated that health risk 
assessments analogous to the pH@W surveys yield similar estimates of prevalence of 
health-related and work-related factors across subsamples with different response, 
even when response percentages are as low as 27% as it was in pH@W 
(3,228/12,007) 23. Using a method described by Hofler and colleagues 24 and Seaman 
and White 25 to address possible bias, the data were weighted in analyses using the 
inverse of the estimated probability of non-response estimated by logistic regression. 
In effect, this method uses the data of respondents to additionally represent the data of 
non-respondents to whom the respondent is comparable in terms of the estimated 
probability of non-response. Inverse probability weighting thus allows inferences to 
be drawn for the initially sampled population, similar to if all survey recipients had 
responded. The probability of nonresponse was estimated using a logistic regression 
model.  
2.3.4 Measuring Multimorbidity 
Multimorbidity was defined with two cut-off count method from a list of 20 pre-
specified health conditions from the World Health Organisation Health and Work 
Performance questionnaire (WHO-HPQ) 26. Respondents indicated (yes/no) whether 
they currently had each of the listed conditions or not, including arthritis or 
rheumatism, chronic back pain, migraine headaches, other frequent or severe 
headaches, any other chronic pain, high blood pressure or hypertension, congestive 
heart failure, coronary heart disease, stomach or intestinal ulcer, irritable bowel 
disorder, chronic heart burn or gastroesophageal reflux disease, asthma, chronic 
bronchitis or emphysema, chronic obstructive pulmonary disease, urinary or bladder 
problems, diabetes, osteoporosis, skin cancer, any other type of cancer and mental 
disorder. Using the count method, the employees then were assigned to one of five 
categories based on their total number of chronic conditions.  
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2.3.5 Measuring Health-related Lost Productive Time  
Three outcomes absenteeism, presenteeism and total lost productive time (LPT) were 
examined during the four-week recall period in this study. Presenteeism was defined 
as “working while ill” while absenteeism was defined as “not attending work when 
ill” 27. The lost productive rate due to presenteeism were captained by the percentage 
on a scale from 0% to 100%. Total LPT was the sum of absenteeism and presenteeism 
days. 
2.3.6 Study Sample 
In Chapter 5, analyses were conducted using data derived from the pH@W. 
Derivation of the sample is presented in Figure 2-1.  
2.3.7 Ethics statement  
Ethics approval for the study described in Chapters 5 was obtained from the Human 
Research Ethics Committee (Tasmania), reference no. H0010501.  
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Figure 2-1. Study sample size described in Chapter 5, derived from the pH@W. 
 
 
  Total in pH@W (n=6,638) 
In 2013 (n=3,228) 
In 2010 (n=3,410) 
Sample size used in Chapter 5 
(n=3,086) 
No response to whether 
“currently have any of a list of 20 
chronic health conditions” (n=3) 
No response to “absenteeism lost 
time” or “presenteeism lost time” 
survey item (n=139) 
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2.4 The notes on the used data sources for Chapter 3 to 5 
While multimorbidity is more prevalent among older persons and in clinical 
populations, it also affects younger persons in the general population. A focus on 
older and/or clinical populations will not capture the full impact of multimorbidity on 
population health. Thus this thesis has a focus on the community-based population 
including working populations.  
There were also other Australian databases collecting multimorbidity-related 
information, such as BEACH and the Household, Income and Labour Dynamics in 
Australia (HILDA). Although BEACH collected data regularly and used a weighted 
scale to identify multimorbidity, as a primary health care survey it was too narrow in 
scope for the purposes of this thesis. Most recently, using BEACH Harrison et al. 
estimated the prevalence of multimorbidity in the Australian general population by 
weighting the data to match the age-sex distribution of the Australian population 28. 
They hypothesised the individuals had no diagnosed chronic conditions if they did not 
visit a GP in the previous year. But this may underestimate the prevalence of some 
chronic conditions which did not require health care in a single year. Although the 
national estimates could be inferred to some extent, a more straightforward analysis is 
preferred. HILDA is a panel survey which has collected information from 17,000 
Australian residents every year since 2001 29. HSU coverage in HILDA only includes 
the number of the doctor visits and hospital admissions for each respondent but no 
other types of HSU. Moreover, its purpose is providing the linkages between the 
different life domains rather than focusing on the health surveillance in which we 
were more interested.  
Meanwhile, other kinds of study design are inappropriate for this thesis for following 
reasons. The randomised control trials are conducted when there is an intervention. 
The case control studies are the observational studies in which two existing groups 
differing in study subjects. This design makes the sample potentially unrepresentative 
of the Australian community 30. However, given that at present there is little known 
about exploring the association of multimorbidity with a series of health outcomes in 
Australian general population, the cross-sectional studies are recognized as an 
appropriate way when the exposures are the point estimate 31 and provide useful 
38 
 
preliminary data to inform future research when with a large nationally representative 
sample.  
The adopted data sources in this thesis, therefore, appeared to be the best data sources 
available to address my study aims at the time each study being conducted. 
2.5 Data analysis 
The methods of data analysis for each individual study are reported in each of the 
relevant chapters of this thesis that details the conduct and results of the studies. All 
analyses were conducted using STATA (StataCorp, College Station, TX, USA). 
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Chapter 3 
 
Chapter 3. Multimorbidity and health-related quality of 
life (HRQoL) in a nationally representative 
population sample: implications of count 
versus cluster method for defining 
multimorbidity on HRQoL 
3.1 Preface 
This chapter aims to understand the associations of multimorbidity with HRQoL in 
the general population, particularly to understand whether the definition of 
multimorbidity matters and how. This work is important because multimorbidity does 
not have a universally accepted method of measurement and the implication of these 
variations has not been explored for HRQoL. Various methods for defining 
multimorbidity have resulted in poor comparability between studies. To our 
knowledge, no study has been conducted to examine whether the association between 
multimorbidity and quality of life varies by methods for defining multimorbidity. The 
findings of this work provide the first evidence on comparability of the association 
between multimorbidity and quality of life across different methods for defining 
multimorbidity, highlighting the urgency of establishing a comprehensive definition 
for multimorbidity as related to HRQoL. This is also important for developing a target 
prevention and intervention for improving HRQoL and potentially other health 
outcomes. 
The material presented here has been published in a peer-reviewed journal 1. 
3.2 Introduction 
The presence of multiple chronic conditions, also known as multimorbidity, is in the 
health care spotlight due to its increasing prevalence, complex management and large 
economic disease burden 2, 3. Approximately 25% adults have at least two chronic 
conditions, and more than half the elderly have three or more conditions 
simultaneously 4. Although the prevalence of multimorbidity is higher among adults 
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aged 65 years and over, more than half of individuals with multimorbidity are 
younger than 65 years 5, 6, which makes multimorbidity an issue across the lifespan. 
HRQoL is a holistic concept that aims to capture a range of health status indices. To 
date, the impact of multimorbidity on HRQoL has been investigated based on two 
general categories of multimorbidity: i) the number of chronic conditions (count 
definition) and ii) the cluster of chronic conditions (cluster definition) 7, 8. Although 
HRQoL scores decrease with an increasing number of co-occurring chronic 
conditions 9, the full impact of multimorbidity on HRQoL is unlikely to be captured 
by the simple count method 10. Meanwhile, some specific clusters of multimorbidity, 
such as the combination of mental and physical conditions 11, have been shown to 
have a notable effect on HRQoL. However, the impact of the different definitions of 
multimorbidity on HRQoL in a primary care setting is still unclear 9. 
Comparing how the aforementioned categorizations of multimorbidity effect the 
sociodemographic profile and health status (HRQoL) will provide a conclusive 
definition of multimorbidity, and consequently, improve health care planning in the 
context of multimorbidity to match healthcare services with patients’ needs. 
Therefore, using a large, nationally representative dataset, this study examined the 
performance of the count and cluster definitions of multimorbidity in determining the 
sociodemographic profile and HRQoL in a general population. 
3.3 Methods 
3.3.1 Study design and participants 
Our study was a cross-sectional analysis of a nationally representative dataset, the 
NSMHWB2007, which consisted of a series of face-to-face interviews conducted by 
the ABS from August to December 2007. Respondents were randomly selected from 
a stratified, multistage area probability sample of respondents’ homes. More 
methodological information could be found elsewhere. 12 There were 14,805 eligible 
dwellings out of an initial sample of 17,352 dwellings due to all household members 
being out of scope or vacant dwellings. Of these, the final data set consisted of 8,841 
respondents (60% response rate) aged 16 to 85 years of age and living in private 
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dwellings. 13 No missing data strategy was used due to the low rate of missing data 
(2.6%): 21 due to no HRQoL score, 34 due to log-transformed HRQoL score, 180 due 
to BMI and 6 due to exercise level. 
3.3.2 Multimorbidity 
Multimorbidity was identified from a pre-specified list including the following self-
reported conditions that significantly contribute to the global burden of illness and 
injury 13-15: asthma, cancer, stroke, CVD, gout, rheumatism or arthritis, diabetes or 
high sugar levels, MDD and anxiety disorder (including agoraphobia, with or without 
panic disorder, GAD and social phobia). Each chronic condition was coded as present 
or absent 13. The diagnosis of mental disorders was established using the World 
Mental Health Survey Initiative version of the Composite International Diagnostic 
Interview version 3.0 (WMH-CIDI 3.0) 15, which is a comprehensive and fully 
structured diagnostic interview. The timeframe was a diagnosis in the 12 months prior 
to the interview. Diagnosis of physical chronic conditions was determined from a pre-
specified list by whether the respondent had ever been told by a doctor or nurse that 
they had these conditions, and stroke was assessed using self-reported stroke 
symptoms 12. 
In the count method, multimorbidity was defined as “two or more” chronic conditions 
occurring at the same time. To test the validation in cut-off of count based method, 
the definition of multimorbidity “having 3+ chronic conditions at the same time in 
one individual” (known as complex multimorbidity) 16 was used as well. In the 
cluster-based method, hierarchical clustering was used to identify the common 
clusters of multimorbidity as chronic health conditions can co-occur via some sharing 
underlying genetic, environmental, or behavioural risk factors 17-19. Assuming N 
variables, the hierarchical approach initially treated each variable as a cluster before 
merging the two closest variables into a new cluster. This step was repeated until all 
variables were merged into one cluster of size N. Jaccard’s coefficient was used to 
calculate the distance of the binary variables (absence or presence of conditions) 17, 20. 
The results may vary depending on the different distance calculation methods. Both 
Ward’s and the average linkage methods have been widely used, with the former 
considered more appropriate for clusters with equal numbers of observations 20 and 
 44 
 
the latter recommended to avoid large or tight compact clusters that result from the 
single linkage and the complete linkage methods 20. Therefore, we used the average 
linkage method in this study and used the cluster stopping rule to aid in selecting 
partitions 21. 
3.3.3 HRQoL 
The AQoL-4D instrument was used to measure quality of life due to its brevity 22, 
sensitivity and robustness 23. Four dimensions (independent living, mental health, 
relationships and senses) consisting of three items each were included for scoring. 
Then, five new variables, four dimension scores and one overall instrument score, 
which ranged from -0.04 to 1, were created. A score of 1.00 indicated the best quality 
of life equal to perfect health, and 0.00 indicated quality of life equal to death, and 
negative values (0 to -0.04) indicated quality of life worse than death 24. 
3.3.4 Covariates 
Univariate analyses with a 0.25 p-value cut-off were performed to screen the 
covariates before the second round of screening, involving multivariate analyses. A 
cut-off of a 10% change in the exposure variable’s coefficient estimate in the 
multivariate model was adopted to identify the “important” variables influencing the 
association between outcome and exposure. Covariates that remained after these 
procedures were utilized throughout all subsequent analyses conducted in this study. 
The covariates screened in this study included sex, age, registered marital status 
(married, unmarried), labour force status (employed, unemployed, not in the labour 
force), area of relative socioeconomic disadvantage (decile 1=most disadvantaged, 
decile 10=least disadvantaged), body mass index (BMI=self-reported weight/self-
reported height2), smoking status (current, ex-smoker, never) and level of exercise 
(low: <1600 min; moderate: 1600-3200 min, or >3200 min but <2 h of vigorous 
exercise; high: >3200 min, including ≥2 h of vigorous exercise), which was also used 
to assess exercise intensity (exercise intensity scores were multiplied by minutes per 
fortnight) 12. 
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3.3.5 Statistical analyses 
Due to the complex survey design used in the NSMHWB2007, a weighting strategy 
was applied to infer results for the total in-scope population by allocating a 'weight' to 
each sample unit. The weight was an indication of how many population units were 
represented by the sample unit 12. As a result, Jack-knife delete-A-group survey 
adjustment replication methods were used to calculate the standard errors (SEs) 25. 
This process accounted for the stratified multistage sampling framework used in the 
NSMHWB2007 and adjusted for non-response, which may cause some groups to be 
over- or under-represented 26. The theory behind Jack-knife delete-A-group 
replication methods is that, the sampling variability between repeated samples can be 
estimated by repeatedly taking random but unbiased sub-samples from the achieved 
sample and then computing the variance of the sub-samples (after taking the smaller 
sample size into account). Jack-knife estimation replicates are created by deleting one 
group at a time, and then weighting the other groups from the same stratum to adjust 
for the removal. Therefore, each replicate provides an unbiased estimate of the 
population mean, and the variance of those estimates provides an estimate of the full-
sample of the variance. In short, application of these methods ensures the sample is 
representative of the Australian population, which ensures that subsequent findings 
are generalizable to Australian adults (n=16,015,000) in 2007 12. 
Frequencies and percentages calculated with jack-knife SEs were used for the 
descriptive analysis. Hierarchical clustering analysis was used to identify common 
clusters of multiple chronic conditions. Linear regression models were used to 
examine the associations between the HRQoL scores and the multimorbidity clusters. 
In each regression model, the dependent variable was the HRQoL score, and the 
independent variable was one cluster (present or absent), for example, “whether 
presenting 2+ chronic conditions” in model-1. The p value for the trend of continuous 
variables in the linear regression models was given. A log-transformed HRQoL score 
was used due to its negatively skewed distribution, which resulted in 55 missing 
values. A two-tailed p-value of <0.05 was considered statistically significant. To test 
the validation in clusters of hierarchical clustering, sensitivity analyses were 
performed that including factor analysis 27, principal component analysis 28 and K-
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means clustering 29, which have been used in previous studies. All analyses were 
performed using Stata/SE Version 12.1 (StataCorp, College Station, TX, USA). 
3.4 Results 
We analysed data from 8841 respondents which could be generalizable to 16,015,000 
Australian adults. The mean age of the study participants was 44 years (SE=0.04). A 
total of 20.5% (SE=0.6) of the population was obese (BMI >30), 65.2% (SE=0.2) 
were employed, 72.7% (SE=0.9) reported low levels of exercise, 53% (SE=0.7) were 
married and 22.3% (SE=0.7) were current smokers. More than half of the respondents 
(56.7%, SE=0.7) had at least one chronic condition, and 46% had two or more chronic 
conditions. (Table 1) 
Table 2 presents the prevalence of each chronic condition and the percentage of 
coexistence with other chronic conditions. CVD (21.2%, SE=0.7), arthritis (19.9%, 
SE=0.6) and asthma (19.6%, SE=0.5) were the three most prevalent conditions. All 
chronic conditions coexisted with other chronic conditions to various degrees (range 
from 49% to 91%). Table 3 presents the two common clusters obtained using 
hierarchical clustering, CVD/arthritis (cluster-1, prevalence=9.2%, SE=0.5) and 
MDD/anxiety (cluster-2, 4.3%, SE=0.3). In contrast, the prevalence of multimorbidity 
as defined by the MM2+ and MM3+ count method were 26% (SE=0.6) and 10.1% 
(SE=0.5), respectively. 
The mean ages of the population with MM2+, MM3+, cluster-1 and cluster-2 were 
54.6 (SE=0.3), 57.5 (SE=0.6), 63.8 (SE=0.7) and 41.7 (SE=0.7) years, respectively. 
As expected, prevalence of MM3+ was lower than MM2+ (Table 3), but mean 
HRQoL was poorer. Interestingly both count methods identified groups with similar 
socio-demographic characteristics such as female, older, higher BMI, lower education 
level, less exercise, lower socio-economic status, and not in the labour force. 
Individuals with MDD/anxiety (cluster-2), which resulting from hierarchical 
clustering to identify multimorbidity, had the lowest HRQoL scores with the different 
socio-demographic characteristics comparing to the other hierarchical cluster and 
count method to identify multimorbidity, such as younger, unemployed, unmarried. 
(Table 4-5) 
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Individuals with MDD/anxiety (cluster-2) had HRQoL scores that were 0.38 points 
(SE=0.02; p<0.01) lower than those without cluster-2. Individuals with any two or 
more chronic conditions (MM2+) had HRQoL scores that were 0.21 points (SE=0.01; 
p<0.01) lower than those with no more than one chronic condition. Individuals with 
any three or more chronic conditions (MM3+) had HRQoL scores that were 0.26 
points (SE=0.02; p<0.01) lower than those with no more than two chronic conditions. 
Individuals with CVD/arthritis (cluster-1) had HRQoL scores that were 0.14 points 
lower than those without CVD/arthritis. After adjusting for sex, age, BMI, labour 
force status, level of exercise (not in the model of cluster-2), registered marital status, 
smoking status and socio-economic disadvantage index, multivariate analyses 
revealed the associations between the HRQoL scores and each cluster remained 
significant; the MM2+ cluster (coef: -0.18, SE=0.01; p<0.01) and the MM3+ cluster 
(coef: -0.23, SE=0.02; p<0.01) were higher than the CVD/arthritis cluster (coef: -0.10, 
SE=0.01; p<0.001) but lower than the MDD/anxiety cluster (coef: -0.36, SE=0.01; 
p<0.001). (Table 6-7) 
3.5 Discussion 
Consistent with the findings of the 2004 systematic review by Fortin et al. 9, our 
analysis of a large, nationally representative dataset showed that multimorbidity is 
common and significantly associated with lower HRQoL. Although the different 
definitions of multimorbidity did not change this association, the sociodemographic 
profiles and HRQoL scores varied depending on the definition of multimorbidity. In 
the present study, the HRQoL scores were lowest in the participants characterized by 
cluster-2 (MDD/anxiety disorders), followed by MM2+, which defined 
multimorbidity as 2+ condition entities, and cluster-1 (CVD/arthritis). 
Although this study failed to identify a specific cluster of comorbid mental and 
physical disorders, previous research has demonstrated that the co-occurrence of 
mental and physical disorders is strongly associated with poorer HRQoL 30. 
Therefore, the findings of this study suggest that the count method does not take the 
type of chronic conditions into account. Therefore, this method can detect the overall 
influence of multimorbidity on the HRQoL, but it does not capture the specific 
disease that contributes to the associated HRQoL. 
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Individual disease-based treatments can help relieve associated discomfort, slow the 
course of disease and increase the HRQoL for people with a single chronic condition. 
However, for individuals with multimorbidity, traditional, individual, disease-focused 
treatment does not perform well due to interactions between the diseases and 
treatments. Moreover, reducing the number of conditions does not provide health 
professionals with an effective therapeutic plan. Furthermore, when calculating the 
burden of multimorbidity, the condition needs to be treated in its entirety if it is to 
inform accurate health care planning. 
Different cut-off values of the number-based count definition of multimorbidity have 
been used in the previous HRQoL studies 31. Some of them used both two or more 
(2+) and three or more (3+) chronic conditions at the same time 16, 32-34 as the cut off 
value. Harrison, Britt 16 reported that the 2+ definition was more appropriate in a 
broader age-scope population, whereas 3+ was more specific for an elderly study 
population 16. However, no cut-off can be used without caution, particularly because 
the number of conditions in the current studies ranged from 4 to 102 34, 35. 
Furthermore, the 2+ cut-off is recommended when a limited number of chronic 
conditions are included in the definition of multimorbidity, whereas the 3+ cut-off 
requires the inclusion of more chronic conditions 16. Despite these issues, the 2+ cut-
off was deemed most appropriate for our study based on the data used, i.e., eight 
chronic conditions and a population-based sample. 
In addition to hierarchical clustering, other approaches to the common clusters of 
multimorbidity exist including factor analysis, principal component analysis and K-
means clustering 17. This study used hierarchical clustering with Jaccard’s coefficient 
due to the shared risk factors among the chronic conditions and the binary nature of 
chronic diseases 20. However, the other three approaches were tested in a sensitivity 
analysis using the same sample (results not shown). The same clusters were produced 
by the factor analysis and principal component analysis: CVD/arthritis (cluster-1) and 
cancer/stroke/CVD/arthritis/diabetes. K-means analysis produced clusters including 
cancer/stroke/CVD/arthritis/diabetes and cancer/stroke/CVD/diabetes/MDD/anxiety. 
Cancer/stroke/CVD/arthritis/diabetes and cancer/stroke/CVD/diabetes/MDD/anxiety 
were not examined further due to the extremely low prevalence, with only five and 
two cases, respectively. These differences may be due to the different mechanisms of 
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the methods used to detect the clusters, i.e., the cluster analysis processes used 
distance measures, whereas the factor analysis and principal component analysis 
processes used correlations. In addition, the individuals within these distance-based 
clusters have more common characteristics. Furthermore, because the results of the 
hierarchical cluster approach may be sensitive to the distance scales and linking 
methods, we performed sensitivity analyses using an additional four distance scales: 
Ward’s linkage, waverage linkage, single linkage and complete linkage. All of these 
scales produced the same results as average linkage, except for single linkage.  To test 
the sensitivity of different cut-off of count-based method, MM3+ as the complex 
multimorbidity in literature was used as well. 16 The results shown that even 
prevalence of multimorbidity as well as the mean HRQoL scores in the people 
considered as multimorbid varied by the different cut-off of multimorbidity used, 
multivariate analyses revealed similar patterns in the variations of estimates of 
HRQoL scores within each of the subgroups of individuals considered. In relation to 
the cluster definitions of multimorbidity, the method does not pre-specify number of 
conditions but is statistically derived, thus these analyses remain unchanged. 
This study has several notable limitations. First, the findings of multimorbidity studies 
must be in considered with reference to the list of conditions included in the definition 
of multimorbidity, as the prevalence of multimorbidity depends on the definition 
used. 35 However, the health conditions used in this study were chosen because they 
contribute significantly to the burden of disease in the Australian community. 
Moreover, the present study excluded acute conditions, which some previous studies 
have included 7. Although including more conditions in the definition of 
multimorbidity may potentially provide a more comprehensive understanding of an 
individual’s health status, acute conditions were not considerate in this study as they 
may only influence health status temporarily 16 and not be relevant to long-term health 
care planning. 
Second, the data used in this study were derived from a survey focused on mental 
health well-being. As a result, the assessments of physical chronic conditions were 
relatively brief, self-reported and not verified using medical records 12. Physical 
conditions were assessed by self-report in the past 12-months, which may be 
underestimated or overestimated due to recall bias. However, the validity of self-
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reported chronic conditions has been indicated in different contexts. 36-40 Moreover, 
self-reported data offers cost-effectiveness and convenience for gathering information 
in the population-based surveys. 41 Finally, despite being encouraged 33, the severity 
of chronic conditions was not included in this study because it was not measured in 
the NSMHWB2007 and the additional burden on the respondents (time consuming) 
may reduce the response rate. Although it is unlikely to change the present status of 
the condition when defining multimorbidity, the severity may have influenced the 
HRQoL scores. 
To our knowledge, this is the first study to compare number-based and cluster-based 
definitions of multimorbidity using nationally representative data. This large 
population-based database, using the delete-1 group jack-knife technique to generate 
the replicate weights, increases the generalizability of the study’s findings and could 
inform the investigation of multimorbidity-related HRQoL in Australia and similar 
economies worldwide. 
3.6 Conclusions 
Our findings confirm the existence of an inverse relationship between multimorbidity 
and HRQoL in the Australian population and indicate that the sociodemographic 
profile and HRQoL vary depending on the method used to define multimorbidity. We 
conclude that from this head-to-head comparison, the hierarchical clustering approach 
has been validated when the outcome of interest is HRQoL. Moreover, a simple count 
fails to identify if there are specific conditions of interest that are driving lower 
HRQoL. From this perspective, the cluster-based methods, resulting in clusters with 
the same shared health conditions, may be more useful and informative. Finally, we 
recommend that researchers exercise caution when selecting a definition of 
multimorbidity because it may significantly influence the study outcomes. 
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Table 3-1. Demographic characteristics of the study population, weighted (N=8,820).  
 
 n % 
Jack-knife standard 
error 
Sex    
Male  4,018 49.7 0.01 
Female 4,802 50.4 0.01 
Age    
Mean of age (yr.) 44  0.04 
16-25yr. 1,551 17.4 0.3 
26-35yr 1,386 18.0 0.3 
36-45yr. 1,586 19.0 0.4 
46-55yr. 1,247 17.5 0.3 
56-65yr. 1,293 14.2 0.2 
66-75yr. 1,069 8.7 0.2 
76-85yr. 688 5.2 0.1 
BMI (kg/m2)     
Thinness (BMI<18.5) 254 2.7 0.2 
Normal (BMI 18.5-24.99) 3,701 42.1 0.8 
Overweight (BMI 25.00-29.99) 2,965 34.7 0.7 
Obesity (BMI >30.00) 1,724 20.5 0.6 
Educational attainment    
Has post-school qualification 4,914 54.8 0.5 
No post-school qualification 3,906 45.2 0.5 
Labour force    
Employed 5,491 65.2 0.2 
Unemployed 215 2.6 0.1 
Not in the labour force 3,114 32.2 0.2 
Level of exercise     
High 597 7.1 0.4 
Moderate 1,754 20.2 0.7 
Low 6,463 72.7 0.9 
Registered marital status    
Unmarried 3,996 47.0 0.7 
Married 4,824 53.0 0.7 
Smoking status    
Current smoker 1,875 22.3 0.7 
Ex-smoker 2,513 26.9 0.7 
Never smoked 4,432 50.8 0.7 
Index of Socio-Economic Disadvantage 
- Area deciles 
  
 
1st decile (lowest) 735 8.1 0.6 
2nd decile 789 8.6 0.8 
3rd decile 975 10.4 0.8 
4th decile 777 8.1 0.8 
5th decile 897 9.7 0.8 
6th decile 890 10.3 0.9 
7th decile 862 10.0 1.0 
8th decile 989 11.8 1.0 
9th decile 896 11.0 0.8 
10th decile (best) 1,010 12.0 0.9 
Number of health conditions    
0 3,556 43.3 0.8 
1 2,725 30.7 0.8 
2 1,501 15.8 0.5 
3 697 6.8 0.3 
4 239 2.5 0.3 
5 79 0.6 0.08 
6 20 0.2 0.06 
7 3 0.02 0.01 
BMI=Body Mass Index. Sample size (n) are showed based on the raw data, proportion (%) are estimated 
with standard error based on the weighting strategy. 
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Table 3-2. Prevalence of single chronic conditions and the percentage with other chronic 
conditions, weighted (N=8,820). 
 
Chronic conditions 
 
n % 
Jack-knife 
standard error 
% with other listed 
conditions 
Asthma  1,783 19.6 0.5 49.0 
Cancer  882 8.3 0.4 70.6 
Stroke  234 2.0 0.1 91.6 
CVD  2,059 21.2 0.7 69.9 
Arthritis  1,989 19.9 0.6 72.7 
Diabetes  700 7.5 0.4 77.5 
MDD  658 7.2 0.4 82.3 
Anxiety Disorder  1,005 11.4 0.4 71.0 
Heart or circulatory condition=CVD. Major depression disorder =MDD. Sample size (n) are showed 
based on the raw data, proportion (%) are estimated with standard error based on the weighting strategy. 
 
Table 3-3. Prevalence of common clusters using count method and hierarchical cluster, 
weighted (N=8,820). 
 
 Components n 
Prevalence 
(%) 
Jack-knife 
standard error 
Methods 
MM2+ any 2 (+) of 8 chronic conditionsa  2,539 26.0 0.6 Count method 
MM3+ any 3 (+) of 8 chronic conditionsb 1,042 10.1 0.5 Count method 
Cluster 1 CVD/Arthritis 934 9.1 0.5 Hierarchical cluster  
Cluster 2 MDD/Anxiety Disorder 399 4.3 0.3 Hierarchical cluster 
CVD=Heart or circulatory condition. MDD=Major depression disorder. MM=multimorbidity. Sample 
size (n) are showed based on the raw data, proportion (%) are estimated with standard error based on the 
weighting strategy. 
a: MM2+ which means having any 2 or more chronic conditions out of asthma, cancer, stroke, CVD, 
gout rheumatism or arthritis and diabetes or high sugar levels, MDD and anxiety disorder. 
b: MM3+ which means having any 3 or more chronic conditions out of asthma, cancer, stroke, CVD, 
gout rheumatism or arthritis and diabetes or high sugar levels, MDD and anxiety disorder. 
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Table 3-4. Mean of AQoL-4D utility scores by sample characteristics using count method to 
identify multimorbidity, weighted (N=8,820). 
 
 MM2+a MM3+b 
 % Mean 
Jack-knife 
standard error 
% Mean 
Jack-knife 
standard error 
Sex       
Male  23.8 0.72 0.01 8.7 0.65 0.02 
Female 27.9 0.69 0.01 11.4 0.61 0.01 
Age       
Mean of age (yr.)  54.6 0.3  57.5 0.6 
16-25yr. 8.9 0.68 0.03 2.4 0.56 0.09 
26-35yr 14.1 0.67 0.02 3.3 0.54 0.05 
36-45yr. 18.7 0.67 0.03 6.9 0.60 0.07 
46-55yr. 26.6 0.68 0.02 9.5 0.57 0.03 
56-65yr. 42.2 0.73 0.01 18.7 0.66 0.02 
66-75yr. 52.8 0.75 0.01 23.1 0.70 0.02 
76-85yr. 58.5 0.70 0.02 27.7 0.63 0.02 
BMI (kg/m2)        
Thinness (BMI<18.5) 19.2 0.63 0.06 5.3 0.34 0.10 
Normal (BMI 18.5-24.99) 20.3 0.71 0.01 6.2 0.66 0.02 
Overweight (BMI 25.00-29.99) 25.7 0.71 0.01 10.8 0.64 0.03 
Obesity (BMI >30.00) 38.4 0.70 0.01 17.4 0.60 0.02 
Educational attainment       
Has post-school qualification 23.8 0.72 0.01 8.5 0.66 0.02 
No post-school qualification 28.4 0.69 0.01 12.1 0.60 0.02 
Labour force       
Employed 18.2 0.74 0.01 5.6 0.64 0.02 
Unemployed 20.5 0.63 0.04 8.7 0.60 0.07 
Not in the labour force 42.0 0.68 0.01 19.4 0.62 0.02 
Level of exercise        
High 17.2 0.75 0.02 7.1 0.67 0.04 
Moderate 23.1 0.77 0.02 8.0 0.69 0.04 
Low 27.5 0.69 0.01 10.9 0.61 0.01 
Registered marital status       
Unmarried 22.9 0.64 0.01 9.1 0.57 0.02 
Married 28.4 0.75 0.01 10.9 0.67 0.02 
Smoking status       
Current smoker 26.5 0.62 0.02 10.7 0.53 0.03 
Ex-smoker 32.8 0.72 0.01 14.2 0.66 0.02 
Never smoked 21.8 0.74 0.01 7.6 0.66 0.02 
Index of Socio-Economic 
Disadvantage - Area deciles 
   
   
1st decile (lowest) 29.9 0.62 0.03 15.8 0.54 0.05 
2nd decile 27.1 0.66 0.03 10.6 0.62 0.03 
3rd decile 29.1 0.65 0.02 13.6 0.59 0.03 
4th decile 28.9 0.66 0.03 10.8 0.59 0.03 
5th decile 29.8 0.70 0.02 13.0 0.64 0.03 
6th decile 25.5 0.74 0.02 9.5 0.70 0.07 
7th decile 26.1 0.72 0.03 9.4 0.64 0.04 
8th decile 24.1 0.76 0.02 6.8 0.66 0.03 
9th decile 21.0 0.76 0.02 6.6 0.67 0.03 
10th decile (best) 20.6 0.77 0.02 7.2 0.67 0.04 
CVD=Heart or circulatory condition. MDD=Major depression disorder. BMI=Body Mass Index. 
MM=multimorbidity. Means are estimated with standard error based on the weighting strategy. 
a: MM2+=2+ conditions. 
b: MM3+=3+ conditions. 
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Table 3-5. Mean of AQoL-4D utility scores by sample characteristics using hierarchical 
cluster to identify multimorbidity, weighted (N=8,820). 
 
 Cluster-1a Cluster-2b 
 % Mean 
Jack-knife 
standard error 
% Mean 
Jack-knife 
standard error 
Sex       
Male  8.6 0.75 0.02 3.7 0.54 0.04 
Female 9.6 0.68 0.01 4.8 0.52 0.02 
Age       
Mean of age (yr.)  63.8 0.7  41.7 0.7 
16-25yr. 0.4 0.41 0.40 3.4 0.57 0.03 
26-35yr 0.6 0.72 0.10 4.6 0.57 0.04 
36-45yr. 3.6 0.75 0.12 6.9 0.54 0.05 
46-55yr. 6.6 0.68 0.03 4.7 0.49 0.05 
56-65yr. 20.3 0.72 0.02 3.4 0.44 0.06 
66-75yr. 28.3 0.75 0.01 2.0 0.53 0.05 
76-85yr. 34.7 0.66 0.02 0.6 0.24 0.13 
BMI (kg/m2)        
Thinness (BMI<18.5) 5.9 0.58 0.17 5.5 0.40 0.10 
Normal (BMI 18.5-24.99) 4.8 0.73 0.02 4.5 0.60 0.03 
Overweight (BMI 25.00-29.99) 9.5 0.73 0.02 3.4 0.47 0.04 
Obesity (BMI >30.00) 17.8 0.68 0.02 4.8 0.48 0.03 
Educational attainment       
Has post-school qualification 7.7 0.75 0.01 4.2 0.54 0.03 
No post-school qualification 10.8 0.67 0.02 4.3 0.51 0.03 
Labour force       
Employed 4.0 0.76 0.02 3.9 0.60 0.02 
Unemployed 2.0 0.67 0.18 8.2 0.53 0.07 
Not in the labour force 20.2 0.69 0.02 4.7 0.40 0.03 
Level of exercise        
High 4.1 0.74 0.04 3.5 0.61 0.04 
Moderate 7.8 0.82 0.03 4.4 0.50 0.05 
Low 10.0 0.69 0.01 4.3 0.53 0.02 
Registered marital status       
Unmarried 6.5 0.64 0.02 5.9 0.49 0.02 
Married 11.4 0.75 0.02 2.8 0.59 0.05 
Smoking status       
Current smoker 5.4 0.61 0.05 8.4 0.49 0.03 
Ex-smoker 14.7 0.72 0.02 3.6 0.54 0.05 
Never smoked 7.8 0.74 0.02 2.8 0.56 0.03 
Index of Socio-Economic 
Disadvantage - Area deciles 
      
1st decile (lowest) 11.5 0.59 0.06 5.9 0.44 0.06 
2nd decile 9.7 0.69 0.03 3.1 0.46 0.05 
3rd decile 11.0 0.66 0.03 5.6 0.42 0.06 
4th decile 9.1 0.65 0.04 6.4 0.53 0.09 
5th decile 11.8 0.69 0.03 5.6 0.47 0.06 
6th decile 9.2 0.81 0.05 3.5 0.59 0.04 
7th decile 10.7 0.76 0.03 4.1 0.56 0.05 
8th decile 7.2 0.78 0.03 3.8 0.65 0.08 
9th decile 5.3 0.77 0.04 3.0 0.59 0.07 
10th decile (best) 7.2 0.74 0.05 2.7 0.63 0.05 
CVD=Heart or circulatory condition. MDD=Major depression disorder. BMI=Body Mass Index. 
MM=multimorbidity. Means are estimated with standard error based on the weighting strategy. 
a: Cluster-1= CVD + Arthritis. 
b: Cluster-2= MDD + Anxiety Disorder. 
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Table 3-6. Mean of AQoL-4D utility scores and linear associations by sample characteristics 
using count method to identify multimorbidity, weighted. 
 
   Model 1 – Present. MM2+a Model 2 – Present. MM3+b 
 Univariate analysis Multivariate analysis Multivariate analysis 
 
Unadjusted 
βc 
Jack-knife 
standard error 
Adjusted  
βd 
Jack-knife 
standard error 
Adjusted  
βd 
Jack-knife 
standard error 
Sex       
Male Ref.  Ref.  Ref.  
Female -0.02 0.01 0.001 0.01 0.002 0.01 
Age       
16-25yr. Ref.  Ref.  Ref.  
26-35yr. -0.04 0.01 -0.05 0.01 -0.06 0.01 
36-45yr. -0.05 0.01 -0.07 0.01 -0.08 0.01 
46-55yr. -0.08 0.02 -0.09 0.01 -0.10 0.01 
56-65yr. -0.09 0.01 -0.04 0.02 -0.06 0.02 
66-75yr. -0.09 0.01 0.02 0.02 -0.01 0.02 
76-85yr. -0.19 0.02 -0.05 0.03 -0.08 0.03 
p for trend <0.05  =0.20  <0.05  
BMI (kg/m2)       
Thinness (BMI<18.5) -0.08 0.05 -0.01 0.01 -0.05 0.03 
Normal (BMI 18.5-24.99) Ref.  Ref.    
Overweight (BMI 25.00-29.99) 0.03 0.01 -0.02 0.01 -0.01 0.01 
Obesity (BMI >30.00) -0.01 0.02 -0.02 0.01 -0.02 0.01 
p for trend <0.05  =0.30  =0.30  
Labour force status       
Employed Ref.  Ref.  Ref.  
Unemployed -0.05 0.03 -0.02 0.03 -0.02 0.03 
Not in the labour force -0.13 0.01 -0.11 0.02 -0.10 0.02 
Level of exercise       
High Ref.  Ref.  Ref.  
Moderate -0.003 0.02 0.01 0.02 0.004 0.02 
Low -0.06 0.02 -0.03 0.02 -0.03 0.02 
Registered marital status       
Unmarried Ref.  Ref.  Ref.  
Married 0.05 0.01 0.08 0.01 0.08 0.01 
Smoking status       
Current smoker Ref.  Ref.  Ref.  
Ex-smoker 0.04 0.01 0.04 0.02 0.04 0.01 
Never smoked 0.09 0.01 0.06 0.01 0.06 0.01 
Index of Socio-Economic 
Disadvantage - Area deciles 
  
    
1st decile (lowest) Ref.  Ref.  Ref.  
2nd decile 0.01 0.02 -0.002 0.02 -0.01 0.02 
3rd decile -0.01 0.02 -0.03 0.02 -0.03 0.02 
4th decile 0.01 0.03 -0.01 0.02 -0.01 0.02 
5th decile 0.03 0.02 0.002 0.02 -0.003 0.02 
6th decile 0.03 0.02 -0.01 0.02 -0.02 0.02 
7th decile 0.05 0.02 0.02 0.02 0.01 0.02 
8th decile 0.07 0.02 0.02 0.02 0.01 0.02 
9th decile 0.07 0.03 0.01 0.02 0.01 0.02 
10th decile (best) 0.09 0.02 0.02 0.02 0.01 0.02 
p for trend <0.05  <0.05  <0.05  
       
Present. MM2+a -0.21 0.01 -0.18 0.01   
Present. MM3+a -0.26 0.02   -0.23 0.02 
Observations   8,605  8,605  
Weighted R2   0.1219  0.1159  
BMI=Body Mass Index.  
Means are estimated with standard error based on weighting strategy. 
a: MM2+=2+ conditions. 
b: MM3+=3+ conditions. 
c: β from univariate linear regression for the associations with HRQoL. 
d: β from multivariate linear regression model with all other variables in the table adjusted for the 
associations with HRQoL. 
Significant coefficients are typed in bold font (p<0.05). 
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Table 3-7. Mean of AQoL-4D utility scores and linear associations by sample characteristics 
using hierarchical cluster to identify multimorbidity, weighted. 
 
   Model 3 – Cluster-1a Model 4 – Cluster-2a 
 Univariate analysis Multivariate analysis Multivariate analysis 
 
Unadjusted 
βb 
Jack-knife 
standard error 
Adjusted  
βc 
Jack-knife 
standard error 
Adjusted  
βc 
Jack-knife 
standard error 
Sex       
Male Ref.  Ref.  Ref.  
Female -0.02 0.01 0.01 0.01 0.01 0.01 
Age       
16-25yr. Ref.  Ref.  Ref.  
26-35yr. -0.04 0.01 -0.06 0.01 -0.05 0.01 
36-45yr. -0.05 0.01 -0.09 0.01 -0.08 0.01 
46-55yr. -0.08 0.02 -0.13 0.01 -0.12 0.01 
56-65yr. -0.09 0.01 -0.08 0.01 -0.09 0.01 
66-75yr. -0.09 0.01 -0.03 0.02 -0.06 0.02 
76-85yr. -0.19 0.02 -0.08 0.02 -0.12 0.02 
p for trend <0.05  <0.05  <0.05  
BMI (kg/m2)       
Thinness (BMI<18.5) -0.08 0.05 -0.05 0.02 -0.05 0.02 
Normal (BMI 18.5-24.99) Ref.  Ref.  Ref.  
Overweight (BMI 25.00-29.99) 0.03 0.01 -0.01 0.01 -0.02 0.01 
Obesity (BMI >30.00) -0.01 0.02 -0.05 0.01 -0.05 0.01 
p for trend <0.05  <0.05  <0.05  
Labour force status       
Employed Ref.  Ref.  Ref.  
Unemployed -0.05 0.03 -0.06 0.02 -0.04 0.02 
Not in the labour force -0.13 0.01 -0.12 0.01 -0.11 0.01 
Level of exercised       
High Ref.  Ref.    
Moderate -0.003 0.02 0.01 0.02   
Low -0.06 0.02 -0.03 0.02   
Registered marital status       
Unmarried Ref.  Ref.  Ref.  
Married 0.05 0.01 0.09 0.01 0.07 0.01 
Smoking status       
Current smoker Ref.  Ref.  Ref.  
Ex-smoker 0.04 0.01 0.05 0.01 0.04 0.01 
Never smoked 0.09 0.01 0.07 0.01 0.06 0.01 
Index of Socio-Economic 
Disadvantage - Area deciles 
  
    
1st decile (lowest) Ref.  Ref.  Ref.  
2nd decile 0.01 0.02 0.002 0.02 0.01 0.02 
3rd decile -0.01 0.02 0.001 0.02 0.01 0.02 
4th decile 0.01 0.03 0.01 0.02 0.02 0.02 
5th decile 0.03 0.02 0.02 0.02 0.02 0.02 
6th decile 0.03 0.02 0.01 0.02 0.02 0.02 
7th decile 0.05 0.02 0.02 0.02 0.03 0.02 
8th decile 0.07 0.02 0.04 0.02 0.04 0.02 
9th decile 0.07 0.03 0.03 0.02 0.04 0.02 
10th decile (best) 0.09 0.02 0.04 0.02 0.05 0.02 
p for trend <0.05  <0.05  <0.05  
       
Present. Cluster1a -0.14 0.02 -0.10 0.01   
Present. Cluster2a -0.38 0.02   -0.36 0.01 
Observations   8605  8605  
Weighted R2   0.0773  0.1427  
CVD=Heart or circulatory condition. MDD=Major depression disorder. BMI=Body Mass Index. 
MM=multimorbidity. 
a: Cluster-1= CVD + Arthritis; Cluster-2= MDD + Anxiety Disorder. 
b: β from univariate linear regression for the associations with HRQoL. 
c: β from multivariate linear regression models with all other variables in the table adjusted for the 
associations with HRQoL. 
d: “level of exercise” was not included in model-4 because it was excluded in confounder selection. 
Significant coefficients are typed in bold font (p<0.05). 
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Chapter 4 
 
Chapter 4. How Australian employees use health services 
of single disease when suffering from 
multimorbidity: Findings from the National 
Health Survey 
4.1 Preface 
This chapter aims to understand the patterns of healthcare service utilization in 
employees with multimorbidity, we: i) characterized diseases according to their 
comorbidity statuses (one-condition or coexisting chronic conditions); and ii) 
determined the associations between multimorbidity and disease-specific healthcare 
service utilization. This work is important, as it is the first to examine the associations 
between multimorbidity and disease-specific healthcare utilization in a nationally 
representative sample of the working population. As the number of employed 
individuals managing work and chronic illness is increasing, these findings can help 
shape future occupational and health services.  
The text that follows is included in a manuscript that has been published in a peer-
reviewed journal 1. 
4.2 Introduction 
Multimorbidity, or the presence of multiple chronic conditions in one individual, is a 
major public health concern 2-4 due to its increasing prevalence, associated cost, and 
often complex medical management.5 Multimorbidity is more common in older age 
groups 3, 6. However, more than half of individuals with multimorbidity are younger 
than 65 years of age (i.e., of working age) 7. The earlier onset of chronic conditions 
also implies younger persons are more likely to experience subsequent chronic 
conditions 4, 8. Most direct healthcare costs in health systems are spent on treating 
multimorbidity 5, 9. In addition employees, who represent 63.4% of the global 
population, are working longer than before, even though have reached their retirement 
age 10. For example, the Australian labour force participation rate for individuals aged 
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55+ years rose from 23% in 1984 to 35% in 2014 11, and one fifth of Australian adults 
had multimorbidity11. Moreover, for males in the 65-74-year-old group, this rate 
increased 11% from 2002-03 to 2011-12; for females, while an increase across all age 
groups has been observed, the largest increase happened in the older age groups 12. 
Therefore, multimorbidity has become a substantial and challenging health and 
economic issue for the current workforce.  
People with multimorbidity have higher overall health service utilization, including 
more frequent and longer hospitalizations, readmissions, and physician visits, than 
people with a single condition 2, 3, 6, 13-15. However, healthcare service utilization is 
multifactorial and potentially subject to measurement error 16. The more health 
conditions a person experiences, the higher the risk of measurement error. As 
healthcare is still predominately delivered according to the individual diseases 3, it is 
useful to understand healthcare service utilisation patterns for diseases when they are 
multimorbid versus not. Additionally, most studies have focused on higher risk 
populations, such as patients who frequently use healthcare services and the elderly, 
who are more likely to present with multimorbidity 17. As a productive workforce is 
central to the economic well-being of a country, understanding how employees use 
healthcare services for single diseases in the context of multimorbidity is essential. 
Particularly to gain the insights into their healthcare demands and reduce the 
consequences of multimorbidity on the workforce, including absenteeism, 
presenteeism and the related lost productive time. However, we were unable to locate 
any studies that reported the associations between multimorbidity and disease-specific 
healthcare service utilization, which referred to a series of single-disease evaluations, 
particularly in the workforce. 
Until recently, the definition of multimorbidity and the included number of health 
conditions studies varied across the studies as no agreed definition existed4. Some 
international institutes, such as the Academy of Medical Sciences18 are calling for 
evidence to progress a consistent definition of multimorbidity. The consequence of no 
unique definition makes the comparison between studies challenging. Therefore, it is 
critical to specify the definition of multimorbidity and the included number of health 
conditions in the studies focusing on multimorbidity.  
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The aim of this study was to examine the association of multimorbidity with disease-
specific healthcare service utilization in a working population. Specifically, we sought 
to: i) characterize employees with a specific chronic condition in terms of their health 
statuses (with or without multimorbidity); and ii) determine the associations between 
the presence of multimorbidity and disease-specific healthcare service utilization 
among employees. 
4.3 Methods 
4.3.1 Study design and participants 
Data were derived from the nationally representative, cross-sectional Australian 
National Health Survey (NHS), which was conducted from March 2011 to March 
2012 19. Initially, 21,108 private dwellings were selected in the sample. This number 
was reduced to 18,355 due to sample loss in the field stage 19. Of these dwellings, 
15,565 (84.8%) were fully or adequately responding households, including 20,426 
persons aged 0 years and over 19. Under or over-representation of particular 
demographic groups, such as working people (under-represented as the survey was 
conducted in private dwellings), was adjusted to ensure sample representativeness19. 
The NHS dataset contains self-reported information on the labour force status and 
healthcare service utilization for each current chronic disease in the 12 months prior 
to the face-to-face interviews conducted among respondents aged 15 years and over 
19. Respondents were classified as employed, unemployed, or not in the labour force 
using the reduced set of the questions from the ABS Monthly Labour Force Survey 19. 
Employed respondents were identified when they had worked in a job, for a business, 
or on a farm in the past week, or had a job but were absent during that week 19. 
However, respondents whose usual work time was less than one hour, unpaid 
voluntary work, and those who were away from work due to workers’ compensation 
but were unsure whether they would return to work for their employers were excluded 
19. Therefore, for the purpose of this study, respondents aged 15 years and older who 
were currently employed at the time of interview were included. 
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4.3.2 Multimorbidity 
Multimorbidity was defined as the concurrent presence of two or more diagnosed 
chronic conditions 20-22. Eight diagnosed chronic conditions that had lasted, or were 
expected to last, six months or more based on a computer-based coding system 
developed by the ABS were collected, including asthma, cancer, CVD, arthritis, 
osteoporosis, diabetes (type 2, type 1 and unspecified type-excluding diabetes which 
was not current, long-term and diagnosed, such as gestational diabetes and diabetes 
insipidus), kidney disease, and mental disorders; these conditions were the most 
commonly experienced and were relevant to policy planning in the Australian 
community. The aforementioned conditions were identified as chronic medical 
conditions by asking whether the patient had “ever been told by a doctor or nurse, still 
current and long-term” and then by asking whether “had lasted at least six months or 
the respondent expected the condition to last six months or longer”. There were 
exceptions for some conditions (e.g., asthma was considered even if the respondent 
reported that asthma was not a current condition but had either experienced 
symptoms/treatment in the past 12 months or answered 'yes' to whether they still had 
asthma attacks).  
4.3.3 Healthcare service utilization 
Information on healthcare service utilization for consultations, including the 
frequency of visits in the past 12 months, was collected for each respondent and each 
chronic condition mentioned above. Self-reported information was collected 
concerning visits to some health professionals [GPs (general practitioners) and 
specialists (e.g., a cardiologist for CVD)], whereas other health professionals (e.g., 
nurses and social workers) were grouped into one category with binary answers 
reporting whether they had been visited at least once in the past 12 months. 
Information for each HSU was recorded only once for each condition group per 
respondent. However, because the respondent might visit a health professional for 
several different conditions during one visit, the number of visits for different 
conditions could not be summed to estimate total number of visits for a given 
individual. For example, a respondent who reported having visited a GP five times for 
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CVD and two times for diabetes might have a total number of GP visits ranging from 
five to seven.  
4.3.4 Covariates 
Univariate analyses with a 0.25 p-value cut-off were performed to identify covariates 
before the second round of screening, which involved multivariate analyses. A cut-off 
of a 10% change in the exposure variable’s coefficient estimate in the multivariate 
model was adopted to identify “important” variables that influenced the association 
between the outcome and the exposure. Covariates that remained after these 
procedures were utilized in all subsequent analyses conducted in this study. The 
following covariates were included in this study: age, gender, non-school qualification 
(having a non-school qualification, including a postgraduate degree, graduate 
diploma/graduate certificate, bachelor degree, advanced diploma/diploma, certificate 
III/IV, or certificate I/II, having a certificate that was not further defined, and not 
having a non-school qualification), and body mass index (BMI=self-reported 
weight/self-reported height2). 
4.3.5 Statistical analyses 
Means, frequencies, and percentages were used in the descriptive analyses. To explore 
the associations of multimorbidity and disease-specific healthcare service utilization, 
logistic and Poisson regression models were used to compare individuals who had 
only one specific chronic condition to multimorbid individuals who had that specific 
chronic condition. Odds ratios were estimated from the logistic regression models for 
visits with other health professionals (excluding GPs and specialists), and relative 
rates were estimated from the Poisson regression models for GP and specialist visits.  
To account for non-responses, national representativeness, and confidentiality, all 
analyses were weighted using replicate weights to infer the results for the total in-
scope Australian population 19. All standard errors (SEs) of the estimates were 
generated by the delete-A-group jack-knife technique 19. The significance level was 
set at α=0.05. Multiple testing was not adjusted23, as this study is an exploratory 
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study, which is mainly for hypothesis generating. The analyses were performed in 
STATA version 10, special edition (StataCorp, College Station, TX, USA) 24. 
4.4 Results 
We analysed data from 10,363 employed participants from a nationally representative 
database. Almost one-quarter of the workforce (23.4%, 95% CI 22.3-24.7) had 
multimorbidity. Of the workforce reporting multimorbidity, 15.2% (95% CI 14.3-
16.1) had two chronic conditions and 8.2% (95% CI 7.5-8.9) had three or more 
chronic conditions. The most prevalent chronic conditions were CVD at 29.1% (95% 
CI 27.9-30.4), followed by asthma (20.0%, 95% CI 18.9-21.2) and mental disorders 
(12.5%, 95% CI 11.7-13.2) (Table 4-1).  
Compared to employees with single conditions, the employees with multimorbidity 
were more likely to be females for the majority of conditions, relatively older, more 
likely to be educated, less likely to be current smokers, more likely to have a higher 
BMI, and less likely to be white-collar workers. Moreover, the prevalence of 
multimorbidity increased with age but was highest in the 45 to 64-year-old age group. 
The prevalence also increased with the income level, except for cases including 
mental disorders, which were highest amongst those in the middle-income quintile. 
There were too few cases of osteoporosis and kidney disease (21 and 22, respectively) 
to estimate accurately (the 95% CI ranges were quite large) and apply a regression 
model (Table 4-2). 
The percentage of employees, who reported visiting a GP at least once in the previous 
12 months prior to the survey interview was higher in most disease groups when 
multimorbidity was present, compared to when only a single condition was present. In 
particular, the employees with multimorbidity were more likely to have a higher 
number of visits. For instance, the employees who visited GPs four times or more 
times were more likely to suffer from multimorbidity for all listed conditions. The 
percentage of multimorbid employees who reported visiting any other health 
professional at least once in the prior 12 months was higher for the employees with 
cancer, arthritis, osteoporosis, CVD, and kidney disease than for the employees with 
only one condition in each condition group (Table 4-3). 
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After controlling for age and gender, multimorbid employees with arthritis had 1.7-
fold (95% CI=1.1-2.2, p<0.001) greater odds of arthritis-specific healthcare service 
utilization of GP visits than employees with arthritis alone. Compared with employees 
with CVD alone, multimorbid employees with CVD had 1.6-fold (95% CI=1.1-2.5, 
P<0.05) greater odds of CVD-specific specialist visits and 2.5-fold (95% CI=1.5-4.0, 
P<0.001) greater odds of CVD-specific visits with other healthcare professionals 
(Table 4-4). Overall, our results suggested that the pattern of disease-specific 
healthcare service utilization varied by condition.  
4.5 Discussion 
The descriptive analyses from this nationally representative survey revealed that the 
majority of multimorbid employees reported higher utilization of disease-specific 
healthcare than the employees with one condition alone, which was consistent with 
previous studies in different populations 3. While a strong association between 
multimorbidity and total healthcare service utilization is well recognized, this study 
found that multimorbidity does not always increase the healthcare service utilization 
for a given disease. The association of multimorbidity with healthcare service 
utilization in employees therefore varies depending on disease type. Examination of 
these nationally representative data is an important part of understanding the further 
healthcare needs of the multimorbid working population, but whether these varying 
healthcare service patterns represent under- or over-utilization of particular services 
cannot be answered from this cross-sectional survey. 
In this study, multimorbid employees with arthritis had more arthritis-specific GP 
visits than employees with arthritis alone, whereas multimorbid employees with CVD 
were not more likely to visit GPs but were more likely to visit CVD specialists than 
employees with CVD alone. Multiple factors can explain these findings. For example, 
because arthritis in itself is inflammatory and its main symptoms are joint pain and 
stiffness, these symptoms may impair a person's ability to perform routine tasks 25, 26. 
Therefore, adults with multimorbid arthritis are more likely to have adverse outcomes, 
such as mental distress, and work disability than adults without arthritis 25. 
Subsequently, these employees may experience greater and more frequent pain, which 
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motivates them to use primary healthcare services more often than employees with 
arthritis alone.  
Multimorbid employees with CVD were more likely to visit healthcare professionals 
(excluding GPs) than employees with CVD alone. One explanation could be that 
CVD, which is the global leading cause of death 27, typically manifests in acute 
events, such as heart attacks and strokes 28. Therefore, adults with CVD who routinely 
visit their GPs, especially those who are asymptomatic, do not change their service-
use models unless they experience an emergency. When acute events do occur, these 
individuals may require tertiary healthcare, and the odds of an acute event occurring 
are compounded when CVD is multimorbid. Alternatively, because GPs are 
considered the “gatekeepers” in the Australian healthcare system, people with 
multimorbid CVD are referred to specialists according to the GP’s professional 
knowledge and opinion even if they are initially asymptomatic and do not actively 
require more healthcare services. 
Coexisting mental-physical disorders lead to higher healthcare service utilization 29. 
However, in this study, multimorbid employees with mental and other chronic 
disorders did not report a higher utilization of any healthcare service. This finding 
could be explained by an increase in the utilization of healthcare for physical 
disorders. In other words, mental disorders themselves are already associated with 
increased healthcare service utilization 30, and their coexistence with other physical 
disorders(s) may not further influence the mental disorder-specific healthcare needs. 
This finding could also be explained by underservicing and the stigma seeking out 
mental health care. However, the presence of mental disorders could aggravate a 
person’s coexisting physical disorders and thus lead to a corresponding increase in 
healthcare service utilization. Because most coexisting physical-mental disorders 
occur in the working-age population 7, 31, the presence of a mental disorder could 
increase total healthcare service utilization rates by exacerbating a person’s symptoms 
or perceptions of a poor health status even though mental disorder-specific healthcare 
service utilization did not increase due to multimorbidity. Further, pooling all mental 
disorder types into one category may have mediated healthcare service utilization for 
severe mental disorders, such as major depression. Healthcare service utilization for 
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the other conditions did not differ between employees with multimorbidity and with 
single conditions alone.  
In Australia, employees with multimorbid conditions that include arthritis or CVD 
require more attention because their additional needs may lead to new diagnoses, 
prescriptions, and lifestyle changes. Moreover, in the Australian, and other similar 
healthcare systems, GPs are the gatekeepers of healthcare delivery and play an 
important role in managing multimorbidity. Therefore, specialists may be unwilling to 
share their expertise with those outside of their area. Subsequently, to plan for the 
healthcare of the growing number of employees who juggle both employment and 
chronic conditions, the provision of integrated and appropriate services by GPs who 
closely coordinate their patient’s care should remain an area of emphasis for future 
studies.  
In contrast to the certainty of single diseases, multimorbidity is more changeable and 
there is no “one-size-fits-all” method to address all issues arising from it. 
Unfortunately, health professionals receive no explicit medical education or training 
in how to prioritize care for persons experiencing multimorbidity. Further, the more 
chronic conditions employees have, the more diseases they want to address at each 
consultation, which makes the health professional’s ability to make treatment 
decisions more difficult. However, the length of a standard consultation (5-25 
minutes) may not be sufficient for even one disease, and this discrepancy may lead to 
the under-treatment of some conditions, particularly when they co-exist with others 32, 
33. 
For employees with multimorbidity, setting disease priorities is unavoidable. The 
most important step is to determine whether to identify these diseases explicitly and 
rationally. The needs of an individual with multimorbidity may vary substantially 
over their life course. Therefore, individuals with CVD or arthritis of working age 
need more attention and may gain greater health improvements if being managed 
appropriately. Moreover, the Australian National Health Survey used in this study 
measured healthcare use for each health conditions, which prohibit the use of 
“normal” count-based or cluster-based methods of defining multimorbidity 34. As 
such, current national population data collection may not address the identified gap. 
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As Tinetti et al (2012) suggest “healthcare should but not shift its current focus from a 
disease orientation to a patient goal orientation” 35 and must be updated to align with 
the clinical reality of multimorbidity. 
This study also revealed the prevalence of multimorbidity in the workforce was 
consistent with previous studies 36 and, whilst it increased with age, was highest in the 
45 to 64-year-old age group. This result may have occurred because the employees in 
this age group are more likely to consent to early retirement when experiencing from 
multimorbidity. However, the pension they receive may not be sufficient to support 
their heavy health and economic burdens due to multimorbidity. This could lead to 
multimorbid employees remaining in the workforce in order to cover the costs 
associated with their diseases in the very near future 37. 
Given no agreed definition, using the other methods to define multimorbidity may 
have produced different results. For example, using the higher cut-off may strengthen 
the negative association of multimorbidity with HSU, and it is possible that more 
health conditions would be identified in addition to arthritis and CVD in this study. 
However, the three cut-off requires more included health conditions and is more 
appropriate to older populations whereas the two cut-off is more appropriate in 
populations with a broader age scope38. Another popular method is questionnaire-
based, such as the CIRS39 and Charlson Index40 which require additional mapping of 
diagnoses from the classification system38. So it is impossible to access these scales if 
the survey like the NHS 2011-12 does not incorporate them. 
A notable limitation of this study was the use of cross-sectional data which meant 
neither directionality nor temporality could be attributed to the associations between 
variables, and causal relationships could not be determined. Further, this study was 
based on self-reported data. That is, diagnoses and healthcare service utilization were 
not clinically verified by professionals, and the participants were asked only about 
main conditions to reduce recall bias 19. However, some conditions were likely under-
reported due to stigma (e.g., mental disorders) and the presence of “silent” conditions 
(e.g., mental/behavioural disorders or diabetes) 41. Finally, due to the confidential 
purpose and the complex multistage cluster sampling of the NHS 2011-12 data, some 
statistical processing such as the differences test between two groups was not allowed 
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within the ABS on-line data query environment, which may lead to interpretation 
difficulty to some extent. However, we provided the 95% CI of each estimate to 
present the magnitude of difference. 
The strengths of this study included the use of nationally representative data, which 
covered approximately 97% of the people living in Australia at the time of the NHS 
19. This broad coverage increases the generalizability of the findings. In contrast to 
other studies 41, 42, this study explored multimorbidity not only in the working-age 
population but also in a population who were actually employed at the time of survey 
completion. This distinction could exclude working-age people who were not in the 
workforce, who likely had different healthcare service utilization needs, and who 
were not influenced by work-related factors. 
4.6 Conclusions 
This study is the first to examine the associations between multimorbidity and 
disease-specific healthcare service utilization using a nationally representative sample 
of employees and a series of chronic conditions. Multimorbidity was common in this 
population. Compared with individuals with other diseases, employees with 
multimorbid conditions including arthritis or CVD required more attention in 
understanding the associations between multimorbidity and health service use.  
Guidelines for the management of multimorbidity are urgently needed, especially 
with the inevitable economic burden imposed by the ageing workforce. Longitudinal 
studies are recommended to understand the progression and impact of multimorbidity 
on healthcare resource utilization over time. However, the very first and most 
important step is updating the way of data collection to align with the clinical reality 
of multimorbidity. 
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Table 4-1. Percentage of chronic conditions in the Australian working population (2011-12).  
Chronic Conditions n % (95% CI) 
CVD 3,175 29.1 (27.9-30.4) 
Asthma 2,150 20.0 (18.9-21.2) 
Mental disorder 1,386 12.5 (11.7-13.2) 
Arthritis 1,295 11.4 (10.7-12.2) 
Cancer  1,070 9.1 (8.4-9.8) 
Diabetes 808 7.1 (6.5-7.7) 
Osteoporosis 204 1.5 (1.2-1.8) 
Kidney disease 148 1.3 (1.0-1.6) 
   
Number of chronic conditions   
 0 4,163 42.4 (41.2-43.7) 
 1 3,506 34.1 (32.9-35.3) 
 2 1,726 15.2 (14.3-16.1) 
 3+ 968 8.2 (7.5-8.9) 
 
CVD=cardiovascular disease. Sample size (n) are showed with crude data, percentage of chronic 
conditions are estimated with weighting strategy. The sample size of working participants was 10,363. 
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Table 4-2. Distribution of socio-demographic characteristics by morbidity category in a 
national working population. 
 Asthma Cancer CVD Arthritis 
 Only In MM Only In MM Only In MM Only In MM 
 n=975 n=1175 n=304 n=766 n=1,258 n=1917 n=325 n=970 
Male (vs. female) 58.2 (54.0-62.5) 44.1 (41.2-47.1) 54.8 (47.9-61.8) 50.4 (45.8-54.9) 54.3 (51.1-57.5) 49.0 (46.3-51.8) 56.2 (49.4-63.1) 44.3 (40.2-48.4) 
         
Age         
 15-24 yrs. 28.6 (25.0-32.2) 11.2 (8.4-14.1) 2.6 (0-5.4) 1.3 (0.1-2.5) 5.9 (3.7-8.0) 4.4 (2.8-6.1) 4.0 (0.4-7.7) 1.0 (0.3-1.6) 
 25-34 yrs. 33.6 (29.9-37.4) 20.8 (18.1-23.6) 6.8 (3.3-10.4) 7.1 (5.0-9.3) 18.7 (15.6-21.7) 9.8 (8.4-11.3) 8.9 (4.9-13.0) 7.0 (5.1-8.9) 
 35-44 yrs. 19.5 (16.2-22.8) 22.3 (19.3-25.4) 28.9 (22.2-35.6) 13.0 (9.8-16.2) 23.9 (21.0-26.8) 18.0 (16.2-19.9) 16.6 (10.5-22.8) 11.0 (8.4-13.6) 
 45-54 yrs. 12.7 (10.0-15.4) 22.1 (19.8-24.5) 32.9 (27.0-38.8) 24.4 (20.7-28.1) 28.3 (26.2-30.5) 28.4 (26.2-30.5) 33.8 (26.2-41.3) 29.4 (25.9-32.9) 
 55-64 yrs. 5.2 (3.7-6.8) 18.9 (16.1-21.6) 23.1 (16.9-29.3) 40.2 (35.9-44.5) 18.9  (16.6-21.2) 30.5 (28.3-32.8) 27.6 (21.3-33.9) 39.4 (35.8-42.9) 
 65+ yrs. 0.3 (0-0.6) 4.6 (3.2-6.0) 5.7 (2.7-8.6) 13.9 (10.2-17.6) 4.3 (3.2-5.4) 8.8 (7.2-10.3) 9.0 (4.5-13.6) 12.3 (9.7-14.9) 
         
 Married (vs. unmarried) 39.6 (35.9-43.3) 49.2 (45.1-53.3) 67.7 (61.9-73.5) 65.5 (61.0-70.0) 64.8 (60.9-68.7) 61.8 (58.6-65.0) 67.0 (60.1-74.0) 64.0 (59.7-68.3) 
         
 Has educational attainment (vs. 
do not has) 
65.9 (62.2-69.6) 72,2 (68.9-75.8) 70.3 (64.4-76.2) 73.1 (69.2-77.1) 71.3 (68.3-74.3) 69.3 (66.6-72.0) 57.8 (49.1-66.4) 69.1 (65.5-72.6) 
         
 Current smoker (vs. non-smoker) 19.3 (15.8-22.7) 20.9 (17.9-23.9) 17.2 (12.5-22.0) 15.6 (11.9-19.3) 16.7 (14.0-19.4) 16.1 (14.2-18.0) 20.6 (14.1-27.0) 16.4 (13.1-19.6) 
         
BMI         
 Thin (>=18.5) 1.7 (0.5-2.9) 1.3 (0.2-2.3) 1.6 (0-4.6) 0.1 (0-0.2) 0.6 (0-1.2) 0.6 (0-1.1) 0.6 (0-1.3) 0.3 (0-0.8) 
 Normal (18.5-24.99) 40.5 (35.4-45.7) 29.6 (25.7-33.6) 35.1 (27.3-42.9) 26.3 (21.5-31.1) 29.9 (26.6-33.1) 23.1 (20.3-25.9) 23.5 (17.3-29.8) 21.4 (17.7-25.1) 
 Overweight (25-29.99) 37.3 (32.9-41.7) 34.2 (30.1-38.3) 40.8 (33.4-48.1) 36.7 (31.6-41.8) 38.9 (35.5-42.3) 35.6 (32.0-39.2) 44.5 (36.0-53.0) 33.1 (28.3-38.0) 
 Obesity (>=30) 20.4 (17.1-23.8) 34.8 (30.9-38.8) 22.5 (16.5-28.5) 36.9 (32.5-41.4) 30.6 (27.4-33.8) 40.7 (37.9-43.5) 31.4 (24.4-38.5) 45.1 (40.7-49.5) 
          
White-collar (vs. blue-collar) 30.8 (26.6-35.0) 24.4 (21.6-27.2) 25.9 (19.8-32.0) 28.8 (24.5-33.1) 31.1 (27.5-34.6) 25.9 (23.5-28.3) 39.3 (30.8-47.8) 28.8 (25.2-32.3) 
         
Gross weekly income level         
 1st-lowest 12.7 (9.9-15.5) 7.2 (5.1-9.2) 6.9 (2.7-11.1) 4.7 (2.7-6.7) 6.3 (4.3-8.3) 5.5 (4.0-6.9) 8.7 (4.6-12.7) 6.2 (4.4-7.9) 
 2nd  13.1 (10.1-16.0) 13.1 (10.6-15.7) 8.9 (4.5-13.2) 14.1 (10.7-17.4) 10.0 (7.7-12.3) 13.3 (11.2-15.4) 16.0 (9.1-22.9) 15.7 (12.2-19.1) 
 3rd  22.1 (18.4-25.7) 24.6 (21.2-28.1) 20.9 (14.1-27.8) 22.4 (18.0-26.7) 22.3 (18.8-25.8) 21.8 (18.6-25.1) 19.9 (14.3-25.6) 25.0 (20.5-29.6) 
 4th  30.9 (27.1-34.7) 27.9 (24.5-31.2) 30.6 (22.7-38.4) 25.6 (21.1-30.0) 28.0 (23.2-32.8) 26.9 (24.1-29.7) 27.6 (19.8-35.4) 27.0 (22.7-31.4) 
 5th-highest 21.2 (18.1-24.3) 27.2 (23.7-30.7) 32.8 (25.5-40.0) 33.3 (28.8-37.9) 33.4 (29.3-37.5) 32.5 (29.5-35.4) 27.8 (21.2-34.4) 26.1 (22.3-30.0) 
MM=multimorbidity. CVD=cardiovascular disease. BMI=Body mass index. Values are % (95%CI). 
Sample size (n) are showed with crude data, percentage and mean times of visits are estimated with 
weighting strategy. The sample size of working participants was 10,363. 
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Table 2. (continue) 
 Osteoporosis Diabetes Kidney Mental 
 Only In MM Only In MM Only In MM Only In MM 
 n=21 n=183 n=191 n=617 n=22 n=126 n=410 n=976 
Male (vs. female) 36.2 (10.2-62.2) 26.4 (18.1-34.6) 47.6 (38.2-57.1) 54.8 (50.1-59.5) 40.6 (8.9-72.2) 43.5 (31.8-55.3) 53.2 (47.0-59.5) 43.0 (39.0-47.0) 
         
Age         
 15-24 yrs. 6.8 (0-20.9) 0.1 (0-0.3) 8.2 (2.3-14.2) 6.0 (2.8-9.3) 23.9 (0-60.6) 3.8 (0.3-7.3) 25.6 (18.9-32.4) 9.6 (6.8-12.3) 
 25-34 yrs. - 4.4 (0-9.4) 20.5 (13.9-27.0) 8.0 (5.1-11.0) 9.9 (0-29.0) 7.7 (2.9-12.5) 24.2 (18.6-29.8) 17.9 (15.1-20.8) 
 35-44 yrs. 40.0 (0-66.3) 8.1 (2.0-14.2) 26.9 (18.1-35.6) 19.5 (15.1-23.9) 28.0 (0.6-55.4) 12.3 (4.9-19.7) 26.6 (20.6-32.6) 23.3 (19.9-26.7) 
 45-54 yrs. 15.6 (0-32.7) 27.4 (19.0-35.8) 24.4 (15.9-32.8) 29.6 (25.4-33.8) 23.3 (0-51.1) 43.8 (31.7-55.9) 14.1 (10.0-18.3) 27.2 (23.2-31.1) 
 55-64 yrs. 25.4 (0.9-49.9) 48.4 (38.4-58.4) 17.4 (8.6-26.2) 28.3 (23.9-32.7) 15.0 (0-33.9) 21.6 (13.7-29.6) 8.2 (5.1-11.4) 17.7 (14.5-20.8) 
 65+ yrs. 12.2 (0-28.9) 11.6 (6.4-16.9) 2.7 (0.6-4.7) 8.5 (6.1-11.0) - 10.8 (4.3-17.3) 1.2 (0-2.5) 4.3 (2.5-6.2) 
         
 Married (vs. unmarried) 33.5 (8.4-58.6) 62.8 (55.4-70.3) 65.7 (57.3-74.1) 58.7 (53.3-64.1) 34.3 (3.8-64.7) 60.4 (49.2-71.7) 33.3 (27.4-39.1) 49.6 (45.1-54.1) 
         
 Has educational attainment (vs. do 
not has) 
53.1 (24.8-81.5) 71.8 (63.0-80.6) 72.1 (64.3-80.0) 69.7 (64.4-75.1) 82.3 (57.7-100) 73.8 (63.6-84.1) 65.3 (58.9-71.8) 70.7 (66.6-74.8) 
         
 Current smoker (vs. non-smoker) 3.9 (0-12.0) 16.4 (10.1-22.7) 21.7 (14.2-29.1) 15.9 (12.3-19.4) 17.4 (0-42.7) 12.8 (5.7-19.9) 30.0 (24.2-35.7) 26.4 (22.5-30.3) 
         
BMI         
 Thin (>=18.5) - 1.7 (0-5.2) - 0.4 (0-1.2) - - 2.1 (0.2-3.9) 1.0 (0.1-1.8) 
 Normal (18.5-24.99) 64.0 (29.2-98.7) 35.1 (24.2-45.9) 31.1 (22.3-40.0) 11.2 (7.6-14.8) 51.5 (12.2-90.9) 25.3 (14.5-36.1) 41.4 (34.5-48.2) 28.0 (23.8-32.3) 
 Overweight (25-29.99) 36.0 (1.3-70.8) 38.6 (26.2-51.1) 34.3 (24.7-43.9) 34.2 (28.5-39.9) 14.1 (0-31.5) 34.9 (23.7-46.0) 27.6 (22.3-32.9) 34.1 (29.1-39.1) 
 Obesity (>=30) - 24.6 (15.3-33.9) 34.6 (25.0-44.2) 54.3 (48.7-59.9) 34.4 (0-70.4) 39.8 (26.9-52.8) 29.0 (22.1-35.8) 36.9 (32.3-41.5) 
          
White-collar (vs. blue-collar) 20.2 (0.5-40.0) 16.4 (8.8-24.0) 28.5 (20.7-36.4) 28.0 (23.5-32.5) 24.0 (0-53.2) 28.4 (19.8-36.9) 30.8 (23.6-38.0) 26.8 (23.4-30.2) 
         
Gross weekly income level         
 1st-lowest 3.8 (0-11.7) 7.8 (2.1-13.6) 10.7 (2.8-18.5) 8.4 (5.0-11.8) 16.0 (0-42.0) 7.7 (1.4-14.0) 13.4 (7.9-18.8) 7.2 (5.0-9.5) 
 2nd  4.9 (0-15.3) 17.2 (10.4-24.0) 10.3 (4.2-16.3) 12.8 (8.9-16.7) 46.7 (3.2-90.2) 16.3 (6.9-25.8) 14.3 (8.8-19.7) 14.1 (10.8-17.4) 
 3rd  32.6 (3.1-62.1) 23.4 (14.2-32.6) 25.5 (16.1-34.9) 23.8 (18.6-28.9) 5.9 (0-16.7) 27.0 (16.4-37.7) 27.3 (20.7-33.9) 30.1 (26.3-33.8) 
 4th  42.9 (10.7-75.1) 27.3 (18.9-35.7) 28.0 (18.8-37.1) 27.7 (23.0-32.3) 22.6 (0-49.8) 15.2 (8.1-22.2) 25.2 (19.3-31.0) 25.6 (21.9-29.3) 
 5th-highest 15.8 (0-37.7) 24.2 (16.2-32.3) 25.6 (18.1-33.1) 27.4 (22.5-32.3) 8.7 (0-22.4) 33.7 (21.3-46.2) 19.9 (14.6-25.2) 23.0 (19.6-26.5) 
 74 
 
Table 4-3. 12-month disease-specific healthcare service utilization of GPs, specialists and 
other health professionals by disease status (alone and coexisting with other conditions). 
 Asthma Cancer CVD Arthritis 
 Only In MM Only In MM Only In MM Only In MM 
 n=975 n=1175 n=304 n=766 n=1258 n=1917 n=325 n=970 
Disease-specific          
GP visits         
0 visit  59.0 (52.6-65.4) 56.0 (50.2-61.8) 36.7 (3.1-70.2) 31.3 (17.0-45.7) 37.4 (32.3-42.5) 36.0 (31.1-40.9) 62.7 (53.2-72.2) 57.8 (52.6-63.1) 
1 visit 24.4 (18.4-30.3) 22.1 (17.7-26.4) 23.3 (3.8-42.9) 32.9 (18.8-47.1) 20.0 (15.8-24.1) 19.7 (16.5-22.9) 27.5 (18.0-36.9) 21.2 (16.8-25.5) 
2 visits  7.5 (4.5-10.5) 11.7 (8.3-15.1) 8.6 (0-27.3) 21.0 (7.6-34.4) 25.0 (20.5-29.5) 20.0 (16.1-23.8) 6.4 (2.2-10.5) 9.8 (6.8-12.7) 
3 visits  6.2 (3.3-9.1) 4.2 (2.1-6.3) 0.6 (0-2.0) 5.0 (0-11.1) 6.3 (3.6-9.0) 6.9 (4.6-9.2) 1.8 (0-3.7) 4.5 (2.7-6.3) 
4+ visits  2.9 (1.1-4.7) 6.0 (3.5-8.6) 30.8 (0-65.9) 9.8 (1.2-18.4) 11.4 (7.9-14.9) 17.4 (14.1-20.6) 1.7 (0.1-3.3) 6.8 (4.9-8.7) 
Specialist visits         
0 visit  98.0 (96.7-99.3) 96.6 (94.8-98.3) 45.9 (13.3-78.6) 42.9 (24.9-61.0) 87.3 (84.0-90.6) 85.0 (81.9-88.1) 80.2 (71.9-88.6) 85.8 (82.8-88.9) 
1 visit  1.2 (0.1-2.2) 1.8 (0.6-3.0) 19.4 (0-39.6) 17.2 (1.2-33.2) 7.9 (5.5-10.3) 8.8 (6.2-11.4) 6.4 (1.8-10.9) 7.3 (5.0-9.6) 
2+ visits  0.8 (0-1.7) 1.6 (0.3-3.0) 34.7 (7.9-61.5) 39.8 (24.0-55.7) 4.8 (2.3-7.3) 6.2 (4.2-8.2) 13.4 (6.4-20.4) 6.9 (4.6-9.1) 
Visit other HP at least once 10.1 (6.1-14.1) 6.1 (3.9-8.3) 24.2 (0-53.0) 26.6 (13.0-40.2) 4.4 (2.4-6.3) 9.9 (7.9-12.0) 17.4 (10.6-24.3) 20.1 (16.4-23.8) 
 Osteoporosis Diabetes Kidney Mental 
 Only In MM Only In MM Only In MM Only In MM 
 n=21 n=183 n=191 n=617 n=22 n=126 n=410 n=976 
Disease-specific HSU         
GP visits         
0 visit  57.3 (29.3-85.3) 45.5 (36.2-54.8) 19.9 (5.2-34.5) 18.1 (9.9-26.3) 42.1 (0-100) 62.1 (40.4-83.8) 37.3 (28.5-46.0) 38.6 (33.5-43.7) 
1 visit  33.2 (6.4-60.1) 28.6 (19.6-37.5) 19.0 (6.5-31.5) 17.9 (11.7-24.2) 33.4 (0-89.3) 12.8 (0-26.2) 24.6 (15.2-33.9) 18.9 (14.5-23.3) 
2 visits  9.4 (0-29.3) 16.7 (6.8-26.6) 23.3 (7.6-38.9) 26.2 (17.3-35.1) - 9.6 (0-22.5) 16.6 (9.9-23.4) 14.6 (10.7-18.5) 
3 visits  - 3.6 (0-7.3) 11.7 (0-25.4) 10.0 (5.0-14.9) 24.5 (0-81.5) 1.8 (0-5.5) 8.7 (5.0-16.8) 9.9 (6.8-13.0) 
4+ visits  - 5.6 (1.0-10.3) 26.1 (8.9-43.3) 27.8 (20.3-35.3) - 13.7 (1.3-26.1) 12.9 (6.7-19.0) 18.0 (14.7-21.2) 
Specialist visits         
0 visit  100 (100-100) 86.5 (79.2-93.8) 60.7 (44.4-76.9) 76.7 (68.7-84.8) 59.2 (0-100) 49.4 (30.9-68.0) 80.4 (73.3-87.4) 80.0 (76.2-83.6) 
1 visit  - 6.1 (1.8-10.4) 17.1 (2.2-32.0) 7.2 (2.8-11.5) 40.8 (0-100) 20.1 (0.4-39.9) 4.3 (0.9-7.6) 3.9 (2.3-5.6) 
2+ visits  - 7.4 (1.8-12.9) 22.2 (9.1-35.3) 16.1 (9.1-23.1) - 30.4 (14.2-46.6) 15.3 (9.0-21.7) 16.2 (12.4-19.9) 
Visit other HP at least once  10.4 (0-22.3) 13.4 (6.6-20.2) 42.8 (26.2-59.3) 38.1 (30.0-46.3) - 2.5 (0-5.8) 28.5 (20.9-36.1) 26.5 (22.8-30.3) 
 
GP=general practitioner. HP=health professional. MM=multimorbidity. CVD=cardiovascular disease. 
HSU=healthcare service utilization. Values are % (95%CI). The sample size of working participants 
was 10,363. 
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Table 4-4. Multivariate analysis of disease-specific healthcare service utilization of GPs, 
specialists and other health professionals associated with employees with specific condition 
only compared to those with specific condition coexisting with other chronic conditions. 
 GPs  specialists  Other HPs  
 RR (95% CI) p RR (95% CI) p OR (95% CI) p 
Asthma N=1087  N=1166  N=1171  
  Only 1.0  1.0  1.0  
  In MM 1.0 (0.7,1.2) 0.823 0.7 (0.2,2.6) 0.634 0.7 (0.4,1.2) 0.160 
       
Cancer N=89  N=90  N=112  
  Only 1.0  1.0  1.0  
  In MM 0.7 (0.1,1.3) 0.365 1.2 (0.5,2.9) 0.749 1.4 (0.1,14.0) 0.796 
       
CVDa N=1302  N=1718  N=1750  
  Only 1.0  1.0  1.0  
  In MM 1.1 (0.8,1.2) 0.680 1.6 (1.1,2.5) 0.03 2.5 (1.5,4.0) <0.001 
       
Arthritisb N=835  N=1031  N=1056  
  Only 1.0  1.0  1.0  
  In MM 1.7 (1.1,2.2) <0.001 0.9 (0.4,1.8) 0.728 1.2 (0.7,2.1) 0.453 
       
Diabetes N=268  N=317  N=329  
  Only 1.0  1.0  1.0  
  In MM 0.9 (0.5,1.2) 0.540 1.0 (0.4,2.3) 0.999 0.9 (0.4,2.0) 0.796 
       
Mental disorder N=814  N=873  N=935  
  Only 1.0  1.0  1.0  
  In MM 1.2 (0.9,1.5) 0.262 0.5 (0.8,2.8) 0.163 1.0 (0.7,1.4) 0.839 
 
GP=general practitioner. HP=health professional. MM=multimorbidity. CVD=cardiovascular disease. 
Poisson regression models were used for the relationship between the number of visits with GP, 
specialists and the multimorbidity status. Logistic regression models were used for the relationship 
between the number of visits with other HP and the multimorbidity status. Significant estimates are 
typed in bold font (p<0.05). Sample size (n) are showed with crude data, rate ratios (RR) and odds 
ratios (OR) are estimated with weighting strategy. The sample size of working participants was 10,363. 
All models adjusted for age and sex, models additionally adjusted for: a: BMI; b: educational 
attainment and BMI.  
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Chapter 6 
 
Chapter 6. A Systematic Review of Cost-of-Illness Studies 
of Multimorbidity 
6.1 Preface 
Previous chapters have focused on the negative associations of multimorbidity with a 
range of health outcomes including health-related quality of life, healthcare service 
utility and lost productivity. In this chapter, we turn to exploring the costs of 
multimorbidity in existing literature. This work is important, as the economic burden 
of multimorbidity is considerable and continues to raise, whereas there is no summary 
evidence of the economic burden of multimorbidity. Therefore, this chapter conducted 
a systematic review aiming to analyse the methods of cost-of-illness (COI) studies on 
multimorbidity and summarize the economic outcomes of multimorbidity, to help us 
outline the current researches on multimorbidity, identify the gaps in order to improve 
and shape future COI studies on multimorbidity.  
The text that follows is included in a manuscript that has been accepted by Applied 
Health Economics and Health Policy on 14 Aug 2017. 
6.2 Introduction 
The term multimorbidity refers to the presence of multiple concurrent chronic health 
conditions in one individual without an index disease 1. Regardless of the specific 
definition of multimorbidity adopted, it is common 2, particularly in the elderly with 
prevalence estimates of 65-98% for those aged >65 years 3-5. Additionally, a growing 
body of evidence has indicated an increasing prevalence of multimorbidity 6. In the 
Netherlands, Uijen and van de Lisdonk found that the prevalence of people with two 
or more chronic health conditions increased from 12.3% to 20.5% in primary care 
from 1985 to 2005 7. In the United States, Ward found that the prevalence of 
multimorbidity increased from 21.8% in 2001 to 25.5% in 2012 using the data from a 
national household survey 8, 9. 
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Multimorbidity is one of the most problematic “chronic health conditions” 10 because 
of the escalating prevalence and its far-reaching health consequences. Multimorbidity 
can have a drastic and lifetime impact, as it is unlikely to be cured. Additionally, 
compared to single health conditions, multimorbidity has been related to poorer 
health-related quality of life 11, 12, higher health service utilization 13, and negative 
occupational consequences 14, such as productivity loss due to presenteeism (e.g., 
‘continuing to work while sick’) and absenteeism. Moreover, healthcare resource 
consumption is expected to increase not only because of the accumulation of chronic 
health conditions but also because of interactions and synergies among health 
conditions present within an individual 15. Given the concurrent changes in 
epidemiology, the use of resources and morbidity-related costs of multimorbid 
conditions are likely to undergo enormous changes as well, especially since uniform 
definition and measure of multimorbidity have been lacking.  
Some researchers have begun to summarize the associations of multimorbidity and 
costs. Lehnert et al. reviewed the literature in 2011 which was restricted to studies of 
older adults only 16. Sambamoorthi et al. conducted a narrative expert review which 
does not meet the criteria for a systematic review, i.e. did not report use of systematic 
review methodology, did not describe a study protocol and therefore was not 
registered on Prospero, did not include a standardised assessment of study quality, and 
did not follow guidelines for reporting systematic reviews (e.g. PRISMA) 17. Our 
review meets all of these criteria and we believe it presents an important and distinct 
contribution to this field. Another advantage of this review was providing the 
breakdown of costs. The aim of this study was two-fold: we first compiled a general 
description of COI methods, and we subsequently systematically reviewed studies on 
the costs of multimorbidity, analyzing the different methods used, summarizing their 
findings on the economic impact of multimorbidity and evaluating the quality of the 
included COI studies. 
6.3 Methods 
6.3.1 Literature review 
104 
 
A literature search was performed in the following electronic databases: PROSPERO, 
Cochrane Library (including the HTA Database, DARE and Cochrane Database of 
Systematic Reviews), Health Economic Evaluations databases (including the NHS 
Economic Evaluation Database (NHS EED) and Health Economic Evaluations 
Database (HEED)), National Institute for Health and Care Excellence (NICE) 
Evidence Services, Google Scholar, Scopus, and PubMed. The search strategy 
combined key words related to multimorbidity, comorbidity and multiple chronic 
health conditions. The search was restricted to papers written in English and 
published since 2000 up to October 2016. The inclusion criteria were peer-reviewed 
COI studies (including cross-sectional, cohort and modeling studies); the exclusion 
criterion was studies focusing on an index disease. The main difference between 
comorbidity and multimorbidity was whether an index disease was specified or not. 
Calculating the costs without distinguishing those two situations may lead to an 
underestimation of the burden of multimorbidity. As in “comorbidity”, allied 
treatments of the dominant disease might also apply to the triggered secondary 
diseases, while in “multimorbidity”, each disease receives relatively independent 
treatments. Therefore, we included “comorbidity” in the search terms primarily 
because of the interchangeable use of the terms “comorbidity” and “multimorbidity” 
in the literature. Then, during the article screening stage, studies were excluded if they 
focused on “an index disease”. Figure 1 illustrates the literature search and selection 
process and presents the reasons for study exclusion. As an example, the search 
strategy for PubMed is shown below. 
(((multimorbidity[Title/Abstract]) OR (multi-morbidity[Title/Abstract]) OR 
(comorbidity[MeSH Terms]) OR (co-morbidity[Title/Abstract]) OR 
((multiple[Title/Abstract]) AND (chronic[Title/Abstract] OR long-
term[Title/Abstract] OR "long term"[Title/Abstract]) AND (illnesses[Title/Abstract] 
OR diseases[Title/Abstract] OR conditions[Title/Abstract]))) AND 
((forecasting[MeSH Terms]) OR (health expenditures[MeSH Terms]) OR 
(spending[Title/Abstract]) OR (costs and cost analysis[MeSH Terms]) OR (cost-of-
illness[Title/Abstract]) OR (cost of illness[Title/Abstract])) AND English[Language] 
AND ("2000"[Date - Publication] : "3000"[Date - Publication])) NOT 
(letter[Publication Type] OR news[Publication Type] OR editorial[Publication Type] 
OR “newspaper article”[Publication Type] OR comment[Publication Type]). 
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All titles and abstracts were screened by two independent reviewers (LLW and LS), 
after which the full texts of all potentially eligible papers were obtained and screened 
by the same two reviewers. For any disagreement, the abstract was set aside for 
further evaluation. After a consensus was reached on the final sample of papers, the 
primary reviewer (LLW) screened the reference lists of the included papers for 
additional papers that fulfilled the inclusion criteria. This review was reported in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines 18. 
Formal international guidelines for quality analyses of COI studies are lacking; 
therefore, relevant information was extracted referring to the British Medical Journal 
Checklist 19 for economic submissions and was adapted for COI studies by Molinier 
et al. 20. Equal weight was assigned to each item of the checklist, and the final score 
was the sum of the 10 individual items. The two reviewers assessed each study 
separately. If there was disagreement between two reviewers at this stage, the paper 
was discussed with reference to the aforementioned COI study checklist until 
agreement was reached.  
This systematic review summarized the results referring to the items of COI methods, 
which have been described elsewhere 19-21. The items included the definition of 
multimorbidity, the epidemiological approach, the perspective of the study and the 
type of costs assessed, resource consumption and unit costs, and sensitivity analyses 
(dimensions shown in Table 6-1 and Table 6-2). 
6.3.2 Presentation of results 
Investigating subgroup heterogeneity in COI estimates represents an area for future 
research 22. Therefore, the included studies had to be stratified and presented by 
different components of costs, with clear explanations of the groups. To make the 
costs comparable, cost estimates were all converted to USD ($), according to the 2016 
exchange rate for each study and each currency, with adjustments over time based on 
the Consumer Price Index (CPI) for the original currency. Costs were reported as 
average annual costs (per-capita costs) unless stated otherwise, because the total costs 
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reported in the different studies varied depending on the included sample sizes. The 
results were synthesized descriptively. 
6.4 Results 
A total of 7,249 studies were identified from the PubMed and Scopus literature 
search. After the titles, abstracts and full text were screened, 19 studies remained. 
Then, we incorporated three studies from other databases that were not identified 
from PubMed and Scopus. With these 22 studies, we screened the references and 
identified four studies that had not been identified in our literature search. Finally, 
twenty-six studies met our criteria (shown in Tables 6-1 to 6-3). The years of 
valuation ranged from 1996 to 2013. Thirteen studies were conducted in the United 
States 3, 23-34, seven in Europe 13, 35-40, two in Australia 41, 42, one each from Canada 43, 
Singapore 44 and Taiwan 45, and two in middle- or low-income regions 40, 46. Overall, 
twenty studies used a prevalence approach 3, 13, 23-28, 30-32, 35, 37-42, 44, 46, seven used an 
incidence approach 27, 29, 33, 34, 36, 43, 45, and only one used an economic model to 
estimate the lifetime costs of multimorbidity 36. The studies analyzed samples ranging 
in size from 1,252 to 292 million 28. Twenty-five studies specified the age range of the 
sample 26. Twenty-one studies calculated estimates in a population 65 years and older 
3, 13, 23-25, 27, 28, 30-32, 35-42, 44-46, eight studies included people under 18 years old 23-25, 28, 
30, 36, 38, 45, and three studies were conducted in children only 33, 34, 43. The average 
annual cost of multimorbidity per capita ranged from $49 40 to $252,313 33, showing 
significant variation by study. Additionally, out-of-pocket (OOP) expenditures ranged 
from $49 40 to $6,858 27, which was lower than public insurance costs. Children with 
three or more life-threatening complex chronic conditions in their last year of life had 
the highest costs ($252,313) 33.  
Identifying multimorbidity 
In total, fourteen studies provided the same, clear definition of multimorbidity, i.e., 
the ≥2 simple count method 13, 23, 29-32, 35, 37-41, 44, 46. Twelve studies estimated the costs 
by number, including five “organ system” and seven “health condition or symptom” 
studies, although they did not refer to the term “multimorbidity”. For other definitions 
of multimorbidity, COI information was very limited. Only four studies accounted for 
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the severity of health conditions when measuring multimorbidity; two of them used 
the Cumulative Illness Rating Scale (CIRS) 35, 37; the Clinical Risk Groups (CRG) 
model 36 and Rx-defined morbidity groups (Rx-MG) 45 were each used only once. The 
number of health conditions included when identifying multimorbidity ranged from 4 
32 to 259 23, 26, 29.  
Epidemiological approach 
Six studies followed an incidence-based approach 27, 29, 33, 34, 36, 43, 45, and twenty 
studies calculated prevalence-based healthcare costs 3, 13, 23-28, 30-32, 35, 37-42, 44, 46. 
Lifetime costs were estimated in only one study 36, and unfortunately, specific 
multimorbidity-related costs were unavailable.  
Perspective of the analysis and costs assessed 
Three perspectives were included: eighteen studies were from the payer’s perspective 
3, 23-31, 34, 36, 39-42, 45, 46, six were from healthcare providers’ perspective 13, 32, 33, 35, 38, 43, 
and two used the societal perspective 37, 44. However, both of the studies from the 
societal perspective defined costs as including only healthcare and social care costs. 
Twelve studies included both medical and non-medical expenditures when 
quantifying direct costs 3, 23, 24, 27, 28, 31, 32, 37, 40-42, 44. 
Estimating resource consumption 
Three approaches can be used to estimate resource consumption: bottom-up, top-
down and econometric 47. While the top-down approach typically requires cost data as 
well as relative risks to calculate population-attributable fractions, the bottom-up 
approach often requires data from multiple sources, and the econometric approach 
often requires only a single dataset 47. Sixteen studies gathered data on resource 
consumption from different departments (bottom-up approach) 3, 13, 25, 26, 29-38, 43, 45. 
One used a combined bottom-up and top-down approach 35. Ten studies extracted 
costs from the single database, called an econometric approach 23, 24, 27, 28, 39-42, 44, 46. 
The follow-up periods included lifetime follow-up in a study that adopted an 
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incidence-based approach 36, six years in one study 45, four years in three studies 29, 33, 
34 and two years in one study 43. 
Valuation of unit costs 
Sources of cost estimations  
Most American studies calculated costs from Medicare payments and the Medical 
Expenditure Panel Survey (MEPS), which provided national, continuous and 
comparable estimates over time. An Irish study used data from primary care 
consultations and outpatient and inpatient visits extracted from family practices 13. 
One study quantified indirect costs 44. Four studies did not provide the unit costs  25, 36, 
38, and one study reported the unit incremental cost only 37.  
Discounting costs 
Studies with time horizon less than one or two years did not normally discount costs. 
In all included studies in this review, costs were not discounted, even in the 
longitudinal studies with more than a two-year follow-up. 
Sensitivity analysis 
None of the studies analyzed or discussed the variables that had a significant impact 
on cost estimates. 
Presentation of results 
The results were clearly presented in most studies and were mainly well explained 
and consistently reported in relation to the methods adopted. Three studies did not 
differentiate costs. Based on the key methodological points, a checklist of questions 
was used with full explanations given for clarity (Table 6-3). For fourteen studies, the 
answer to seven of ten questions was “yes”, and all the studies were scored “no” on 
question 9 “Were the major assumptions tested in a sensitivity analysis?” Questions 3 
“Were direct/indirect costs sufficiently disaggregated?” and 7 “Were unit costs 
appropriately valued?” received fewer “yes” answers than the other questions. In one 
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American study 24, the costs were sufficiently disaggregated only for single 
conditions, and the costs of multimorbidity were presented only as additional or 
supplementary information. 
6.5 Discussions 
We systematically reviewed 26 COI studies on multimorbidity without restricting the 
studies to any specific definition of multimorbidity, and this broad inclusion 
contributed to a comprehensive understanding of multimorbidity and its economic 
burden. The costs of multimorbidity ranged from $49 40 to $252,313 33 annual per 
capita and increased according to the level of multimorbidity within each study. We 
found a relative paucity of data on the costs of multimorbidity, but the available data 
still provided valuable information for us to better elucidate the current magnitude of 
the economic burden of multimorbidity. Methods were highly heterogeneous 
producing a wide range of COI estimates. Even at the lower bounds, these costs were 
substantial.  
Costly multimorbidity 
The proportion of costs due to multimorbidity in relation to the total costs ranged 
from 3.4 to 97.8%. Most (n=18) estimates were 60% and above. One study with an 
extraordinarily low estimate (3.4%) 42, which seemed inconsistent with the other 
studies, only evaluated three-month cases of out-of-pocket (OOP) expenditures in 
Australia. The conditions included in the study were all chronic, which required 
ongoing treatment 48, and the short duration of the study may not have reflected all 
incurred costs.  
The highest costs of multimorbidity per person occurred in the last year of life among 
children with life-threatening conditions ($252,313) 33. The costs in all three studies 
with young respondents ranged from $8,551 34 to $252,313 33 and did not include 
direct non-medical or indirect costs. Although the childhood prevalence estimates of 
chronic health conditions ranged from 0.22% to 44% 49, which was much lower than 
the 12.9% to 95.1% prevalence of multimorbidity in the broader age groups 50, 
multimorbid children and their families still faced substantial financial pressure. 
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Moreover, the included studies indicated a persistence of high costs in the following 
years.  
Heterogeneity of multimorbidity COI studies 
Three relevant perspectives of the costs of multimorbidity were included. The societal 
perspective, including care costs, was used in two studies, but they did not account for 
the costs of productivity loss due to multimorbidity 51, including presenteeism, 
absenteeism, premature retirement and death, which are responsible for a substantial 
proportion of the financial burden 52. Information about productivity loss, premature 
retirement and death could be derived from the working population. Only one 
Australian study in this review was conducted among working-age adults and 
included those who were not in the workforce 29. Unemployed populations are more 
likely to have more chronic conditions than employed groups 51. However, that study 
did not estimate productivity loss, which could have been addressed with the available 
data.  
Six studies adopted a cohort study design, with follow-up periods ranging from two to 
six years. The remaining twenty studies used cross-sectional data, which reflect only 
the time of data collection and are limited in their ability to draw valid conclusions 
about associations or possible causality 53. Compared to other reviews of COI studies 
on a specific single disease, this review on multimorbidity included fewer cohort 
studies 54. Data collection over a long period of time is difficult and time- and cost-
intensive; however, modeling designs could compensate for these challenges 55. In 
this review, only Carreras et al. simulated individual costs until death using a 
stationary Markov chain under the assumption that transition probabilities were 
constant 36. This approach was not consistent with the nature of chronic conditions, in 
which health states change dynamically, and modeling of chronic conditions should 
consider this difference 55. However, the lifetime multimorbidity costs could be 
reasonably predicted in this regional study. 
Several studies did not fully describe their methods and were thus difficult to assess. 
This ambiguity might be due to a general lack of economic awareness in the medical 
journals that support economic studies. A community-based cohort ensures a more 
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representative patient population, but the diagnosis of this cohort may rely on self-
reported data, which are certainly less precise. However, the included studies confirm 
multimorbidity is costly. 
Given different healthcare systems, OOP payments varied across countries, but OOP 
expenditure of multimorbidity is always greater than that of non-multimorbidity. For 
example, in China, the patients with multimorbidity have higher OOP expenditure 
than those without multimorbidity, even among those with health insurance 40. 
Findings from economic studies in different countries or regions cannot be easily 
generalized due to monetary issues; for example, different currencies have different 
purchasing power for the same product 56. 
Definitions of multimorbidity 
It is well known that there is no singular definition of multimorbidity, and the two cut-
off count method is generally the most broadly accepted definition used. In this 
review, we found that all the COI studies that provided a definition of multimorbidity 
adopted only this method. Most of the studies that did not specifically define 
multimorbidity also presented costs by the number of multimorbid conditions. Using 
the same definition increased the comparability within the available COI studies.  
The number of included health conditions used to identify multimorbidity ranged 
from 4, which were highly prevalent, disabling or expensive conditions in an 
American community 32, to 259, which included all conditions in clinical 
classification systems 29. The costs did not increase as more conditions were included. 
The wide variation in severity within specific conditions 57 could produce different 
costs. For example, children with life-threatening conditions had the highest 
healthcare expenditure in this review 33.  
Using a cut-off of two or more conditions, the proportional increase in cost for 
multimorbid compared to non-multimorbid ranged from 100% to 1500%, while from 
100% to 900% when using the three cut-off count method. Nevertheless, interpreting 
these quantitative results is problematic because of the different approaches used. 
Domestic characteristics within each country or region, such as clinical practice 
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settings and healthcare systems, also affect resource consumption and unit costs. For 
example, medication costs can vary among studies because of the use of tariffs in 
solidarity systems, which are not comparable to free prices in private systems. 
The different methodologies used to identify multimorbidity led to the wide range in 
expenditures reported above. The number and diversity of available studies on 
multimorbidity provide an insufficient scientific basis for further explorations on 
multimorbidity. Therefore, it is vital to improve the methodological quality of 
multimorbidity COI research to gain a better understanding of this common and 
important phenomenon. Moreover, further research is needed to clarify the costs of 
multimorbidity from the societal perspective.  
Limitations and strengths 
The results of this review are limited by the nature of the studies identified. The main 
limitation of this review is its inability to include all relevant studies. Costs were 
estimated in 16 countries or regions from 1996 to 2013. The large number of abstracts 
derived from the databases improved the sensitivity of our search strategy. The 
absence of a MeSH term for multimorbidity is a clear limitation. However, adding 
multimorbidity-related terms from previous studies to our search strategy helped 
circumvent this limitation. We included papers published in English only, which 
restricted our sample to some extent. The OOP can vary widely between countries 
because of different health insurance systems and types of diseases, therefore, we 
have only reported the range of OOP payment in different countries. Based on the fact 
that multimorbidity is not prevalent in the young population, the pediatric 
multimorbidity studies were rare, therefore, the costs of multimorbidity could not be 
distinguished by age and the finding of pediatric studies in this review was limited. 
Moreover, the practicality of COI studies themselves in aiding policy decision-
making has been debated 58, 59, and their inability to prioritize resources has been 
criticized as well 60, 61. COI studies, which aim to identify and measure all costs of 
health condition serve a different purpose than other health economic evaluations 
(e.g., cost-benefit, cost-effectiveness, and cost-utility analyses), which aim to assess 
both costs and outcomes of the adopted intervention/policy 62-64. However, COI 
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studies can provide useful information as long as they adhere to standardized and 
acceptable methodologies 65, 66. Furthermore, the results of COI studies have been 
used by organizations such as the World Bank and the World Health Organization to 
estimate public, private and total national health expenditures globally 67. Different 
stakeholders can utilize COI studies for different purposes 68. For example, 
governments can estimate the financial impact of a disease on public budgets for 
resource allocation purposes, whereas pharmaceutical corporations can identify 
diseases with high management costs and direct research and development 
investments accordingly. However, caution is warranted when using COI studies; for 
optimal resource allocation, they should be used in combination with other thorough 
economic evaluations 69. 
Despite these limitations, this review provides an overview of the range of estimates 
reported in recent decades, and the collated evidence provides a greater understanding 
of the COI of multimorbidity than the results provided by individual studies. 
Moreover, this review adds systematic evidence about the methodologies used to 
analyze multimorbidity costs and provides insight into the reasons for the disparate 
results among studies. Although multimorbidity complicates the findings of COI 
studies, this review can be useful for informing decisions about the prioritization of 
resources 70, 71, particularly when combined with other economic assessments. 
6.6 Conclusion 
Noting the substantial methodological variations between studies, multimorbidity was 
associated with a considerable economic burden. Although this review identified two 
studies estimating the costs from a societal perspective, there was a consistent theme 
throughout the included studies that those with multimorbidity had higher costs than 
those without multimorbidity. Future research should focus on improving the methods 
of estimating costs. A closer agreement of definition of multimorbidity is still 
required to allow consistent comparisons and enhance the interpretation of study 
findings among future studies.  
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Figure 6-1. Flowchart illustrating the search process. 
 
Articles excluded due to index disease 
(n=11) 
PubMed search (n=2,583) 
Scopus search (n=4,666) 
Duplicates (n=1,565) 
Articles retrieved (n=5,684) 
Articles excluded after screening of title and 
abstract (n=5,654) 
Articles retrieved and 
reviewed in full text (n=30) 
With PROSPERO, Cochrane Library 
(including HTA-Health Technology 
Assessment Database, DARE-Database of 
Abstracts of Reviews of Effects and 
Cochrane Database of Systematic Reviews), 
Health Economic Evaluations databases, 
National Institute for Health and Care 
Excellence (NICE) Evidence Services, 
Google Scholar, additional articles (retrieved 
and reviewed in full text) were not already 
identified by the PubMed & Scopus search 
(n=3) 
 
Additional articles (retrieved and reviewed 
in full text) from the references of 23 articles 
which were not already identified by the 
searches above (n=4) 
Included Articles (n=26), of which n = 19 are from PubMed & Scopus, n=3 are 
additional articles search not from PubMed & Scopus, and n=4 are from references 
search 
Articles retrieved (n=22) 
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Table 6-1. Methodology of included cost-of-illness studies in multimorbidity. 
Study Country Perspective Epidemiological approach Study design Year of valuation Currency 
Hwang et. al 23 USA Payer (OOP) Prevalence Cross-sectional 1996 USD 
Garis et. al 24 USA Payer (public insurance) Prevalence Cross-sectional 1995 USD 
Wolff et. al 3 USA Payer (public insurance) Prevalence Cross-sectional 1999 USD 
Anderson et. al 25 USA Payer (public insurance) Prevalence Cross-sectional 1998 USD 
Thorpe et. al 26 USA Payer (public insurance) Prevalence Cross-sectional 1987 USD 
Thorpe et. al 26 USA Payer (public insurance) Prevalence Cross-sectional 1997 USD 
Thorpe et. al 26 USA Payer (public insurance) Prevalence Cross-sectional 2002 USD 
Schoenberg et. al 27 USA payer (OOP) Prevalence/incidence Cross-sectional 1998 USD 
Schoenberg et. al 27 USA Payer (OOP) Prevalence/incidence Cross-sectional 2002 USD 
Paez et. al 28 USA Payer (OOP) Prevalence Cross-sectional 2005 USD 
Glynn et. al 13 West of Ireland (national representative) Health care providers Prevalence Cross-sectional 2009 EUR 
Naessens et. al 29 USA Payer Incidence Cohort (4 years follow-up) 2007 USD 
Nagl et. al 35 Germany Health care providers Prevalence Cross-sectional 2010 EUR 
Carreras et. al 36 the county of Baix Empordà in Catalonia (Spain) Payer (public insurance) Incidence cohort (lifetime) 2007 EUR 
Kuo et. al 45 Taiwan payer (public insurance) Incidence Cohort (6 years follow-up) 2010 USD 
Lochner et. al 30 USA Payer (public insurance) Prevalence Cross-sectional 2011 USD 
Machlin et. al 31 USA Payer (public insurance) Prevalence Cross-sectional 2009 USD 
McRae et. al 41 Australia Payer (public insurance) Prevalence Cross-sectional 2009 AUD 
Heider et. al 37 Germany Payer (OOP) Prevalence Cross-sectional 2009 EUR 
Orueta et. al 38 Basque country (region in Spain/France) Societal Prevalence Cross-sectional 2011 EUR 
Pati et. al 46 India Health care providers Prevalence Cross-sectional 2007 INR 
Bahler et. al 39 Switzerland Payer Prevalence Cross-sectional 2013 Swiss francs 
Lee et. al 40 China Payer (OOP) Prevalence Cross-sectional 2010 CNY 
Lee et. al 40 Ghana Payer (OOP) Prevalence Cross-sectional 2010 GHC 
Lee et. al 40 Mexico Payer (OOP) Prevalence Cross-sectional 2010 INR 
Lee et. al 40 Russia Payer (OOP) Prevalence Cross-sectional 2010 MXN 
Lee et. al 40 South Africa Payer (OOP) Prevalence Cross-sectional 2010 RUB 
Lee et. al 40 India payer (OOP) Prevalence Cross-sectional 2010 ZAR 
Meraya et. al 32 USA health care providers & payer Prevalence Cross-sectional 2011 USD 
Picco et. al 44 Singapore societal Prevalence Cross-sectional 2013 SGD 
Carpenter et. al 42 Australia payer (OOP) Prevalence Cross-sectional 2009 USD 
Cohen et. al 43 Canada health care providers Incidence Cohort (2 years follow-up) 2005-2007 CAD 
Ananth et. al 33 USA health care providers Incidence Cohort (4 years follow-up) 2012 USD 
Zhong et. al 34 USA payer (public insurance) Incidence Cohort (4 years follow-up) 2004 USD 
 
OOP, out-of-pocket; USA, United States of America; USD, United States Dollar; EUR, Euro; AUD, Australian Dollar; INR, Indian Rupee; CNY, Chinese Yuan; GHC, Ghana Cedi; MXN, Mexican Peso; RUB, 
Russian Rouble; ZAR, South African Rand; SGD, Singapore Dollar; CAD, Canadian Dollar.  
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Table 6-2. The definition, measure, costs of multimorbidity. 
Study 
Definition of
 MM 
Measure of MM 
Number of included c
onditions 
Age range
 (y.o.) 
Prevalence of MM 
(%) 
%(MM) of t
otal costs 
Direct costs  Average costs of MM ($)* MM/non-MM 
Direct me
dical costs 
Direct non-me
dical costs 
Indirect
 costs 
MM2+ MM3+ MM2+ MM3+ 
Hwang et. al 23 MM2+ Count 259 0-80+ 17.0 38.1 yes no no 1387 1733.0 3 3 
Garis et. al 24 NS Count 9 0+ NA NA yes yes no 7938 NA NA NA 
Wolff et. al 3 NS ACG 3493 65+ 65(MM2+)/43(MM3+) 95.3 yes yes no 10627 14276.0 11 10 
Anderson et. al 25 NS Count NS 0+ NA NA yes no no NA NA NA NA 
Thorpe et. al 26 NS Count 259 NS 76.4 92.2 yes no no 13330 14989.8 6 3 
Thorpe et. al 26 NS Count 259 NS 80.5 95.1 yes no no 10950 12158.8 5 4 
Thorpe et. al 26 NS Count 259 NS 86.2 97.2 yes no no 11666 12864.0 6 5 
Schoenberg et. al 27 NS Count 8 65+ 58.1 70.6 yes yes no 3858 4109.0 2 2 
Schoenberg et. al 27 NS Count 8 65+ 70.4 78.6 yes yes no 6856 7687.6 2 2 
Paez et. al 28 NS Count NS 0+ 24(MM2+)/13(MM3+) 48.5 yes yes no 1844 2306.0 16 4 
Glynn et. al 13 MM2+ Count 147 50+ 66.2 82.5 yes no no 2211 2602.0 2 2 
Naessens et. al 29 MM2+ Count 259 18-64 54.3 82.5 yes no no 13285 16245.0 4 4 
Nagl et. al 35 MM2+ CIRS 33 65+ 86.4 94.8 yes no no 3778 4422.0 2 2 
Carreras et. al 36 NS CRG model 
all 857,385 ICD codes 
(815,227 diagnostics a
nd 42,158 procedures) 
0+ 17.8 NA yes no no NA NA NA NA 
Kuo et. al 45 
NS counting the numb
er of Rx-MG 
55 0-71 80 
NA yes 
no no 1045 NA 4 NA 
Lochner et. al 30 MM2+ Count 15 0+ 67.3 92.6 yes no no 13949 NA 6 NA 
Machlin et. al 31 MM2+ Count 20 18+ 25.0 60.3 yes yes no 11934 NA 4 NA 
McRae et. al 41 MM2+ Count 6 50+ 55.8 81.0 yes yes no 1781 2014 2 2 
Heider et. al 37 MM2+ CIRS-G 14 57-84 NA 74.0 yes yes no NA NA NA NA 
Orueta et. al 38 MM2+ ACG 52 0+ 23.6 63.6 yes no no NA NA NA NA 
Pati et. al 46 MM2+ Count NS 18+ 1.3-30.6 NA yes no no 240 NA NA NA 
Bahler et. al 39 MM2+ Count 22 65+ 76.6 94.7 yes no no 8233 NA 5 NA 
Lee et. al 40 MM2+ Count 9 18+ 
1.4% in 18–29 years ol
d to 40.0% in those age
d 70+ years 
NA yes yes no 655 NA NA NA 
Lee et. al 40 MM2+ Count 9 18+ NA yes yes no 92 NA NA NA 
Lee et. al 40 MM2+ Count 9 18+ NA yes yes no 165 NA NA NA 
Lee et. al 40 MM2+ Count 9 18+ NA yes yes no 151 NA NA NA 
Lee et. al 40 MM2+ Count 9 18+ NA yes yes no 49 NA NA NA 
Lee et. al 40 MM2+ Count 9 18+ NA yes yes no 60 NA NA NA 
Meraya et. al 32 MM2+ Count 4 21+ 100.0 NA yes yes no 12317 16454 NA NA 
Picco et. al 44 MM2+ Count 10 60+ 51.5 80.7 yes yes no 11167 NA 2 NA 
Carpenter et. al 42 NS Count 11 50+ 71.1 3.4 yes yes no 4447 3415 3 2 
Cohen et. al 43 NS Count 9 organ systems 0-16 6.7 NA yes no no 36434 NA NA NA 
Ananth et. al 33 NS Count 9 organ systems 0-17 66.1 88.59 yes no no 252313 360046 4 4 
Zhong et. al 34 NS Count 20 1-19 17 44.84 yes no no 8551 15797 4 6 
 
*All costs are in $ (1 EUR=1.0886 USD;1 AUD=0.762966 USD;1 INR=0.014948 USD;1 CHF=1.005635 USD;1 CNY=0.143719 USD;1 MXN=0.049118 USD;1 RUB=0.016234 USD;1 ZAR=0.071561 USD;1 
SGD=0.717926 USD; December 18, 2016). ACG, Adjusted Clinical Groups; Rx-MG, Rx-defined morbidity groups; CRG, Clinical Risk Groups; CIRS, Cumulative Illness Rating Scale; CIRS-G, Cumulative Illness 
Rating Scale for Geriatrics; ICD, the International Classification of Diseases; MM, multimorbidity; MM2+, two-cutoff count method of multimorbidity; MM3+, three-cutoff count method of multimorbidity; y.o., years 
old; NS, not specific; NA, not available.  
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Table 6-3. Answers to the methodological questions by study. 
Questions/answers 
All 
studies 
Hwang 
et. al 23 
Garis 
et. al 
24  
Wolff 
et. al 3 
Anderson 
et. al 25 
Thorpe 
et. al 26 
Schoenberg 
et. al 27 
Paez 
et. al 
28 
Glynn 
et. al 13 
Naessens 
et. al 29 
Nagl 
et. al 
35 
Carreras 
et. al 36 
Kuo et. 
al 45 
Lochner 
et. al 30 
Machlin 
et. al 31 
1 Was a clear definition of the illness given?  1 p p 0 p p 0 1 1 1 p p 1 1 
2 Were epidemiological sources carefully described?  1 1 1 P 0 1 1 1 0 1 p 1 1 1 
3 Were direct/indirect costs sufficiently disaggregated?  1 0 0 0 0 0 1 1 0 1 0 0 0 0 
4 Were activity data sources carefully described?  1 1 1 1 1 1 1 1 0 p p 1 1 p 
5 Were activity data appropriately assessed?  1 1 1 0 p 1 1 1 p 1 1 1 1 p 
6 Were the sources of all cost values analytically described?  1 0 0 0 1 1 1 1 0 1 1 1 p 0 
7 Were unit costs appropriately valued?  1 1 1 1 1 1 1 1 1 1 p 1 1 1 
8 Were the methods adopted carefully explained?  p 1 1 p p 1 1 1 0 1 1 1 p p 
9 Were the major assumptions tested in a sensitivity analysis?  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
10 Was the presentation of study results consistent with the 
methodology of the study? 
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
                
Total score by study                
YES(1) 165 8 6 6 3 4 7 8 9 3 8 4 7 6 4 
NO(0) 58 1 3 3 5 3 2 2 1 6 1 2 2 2 3 
PARTIALLY(p) 37 1 1 1 2 3 1 0 0 1 1 4 1 2 3 
 
Table 6-3. (Continuous) 
Questions/answers 
All 
studies 
McRae 
et. al 41 
Heider 
et. al 37 
Orueta 
et. al 38 
Pati 
et. al 
46 
Bahler 
et. al 39 
Lee 
et. al 
40 
Meraya 
et. al 32 
Picco 
et. al 
44 
Carpenter 
et. al 42 
Cohen 
et. al 43 
Ananth 
et. al 33 
Zhong 
et. al 34 
1 Was a clear definition of the illness given?  1 1 1 p 1 1 1 1 p p p p 
2 Were epidemiological sources carefully described?  1 1 1 1 1 p 1 1 1 1 1 1 
3 Were direct/indirect costs sufficiently disaggregated?  0 p 1 1 1 1 0 1 1 0 0 0 
4 Were activity data sources carefully described?  1 1 1 1 1 1 p p 1 1 1 p 
5 Were activity data appropriately assessed?  1 1 1 1 1 1 1 1 1 1 1 p 
6 Were the sources of all cost values analytically described?  1 p 1 p 1 1 0 1 1 p 1 1 
7 Were unit costs appropriately valued?  1 1 1 0 0 0 0 1 1 1 1 1 
8 Were the methods adopted carefully explained?  1 1 p 1 1 p 1 1 1 1 1 1 
9 Were the major assumptions tested in a sensitivity analysis?  0 0 0 0 0 0 0 0 0 0 0 0 
10 Was the presentation of study results consistent with the methodology 
of the study? 
 1 1 1 1 1 1 1 1 1 1 1 1 
              
Total score by study              
YES(1) 165 8 7 8 6 8 6 5 8 8 6 7 5 
NO(0) 58 2 1 1 2 2 2 4 1 1 2 2 2 
PARTIALLY(p) 37 0 2 1 2 0 2 1 1 1 2 1 3 
 
Total score by study is the sum of answers. P, partially.  
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Chapter 7 
 
Chapter 7. Discussions 
This chapter discusses the findings and implications of this thesis and places them in 
the context of the international literature. First, the methods are revisited, then the 
study findings are summarized, followed by a discussion of the implications of this 
research for the measurement and surveillance of multimorbidity, and, finally, 
recommendations for future research in this field are provided.  
In addition, this thesis aimed to accomplish the following: 
i. To explore the associations between multimorbidity and HRQoL [Chapter 3], HSU 
[Chapter 4], LPT [Chapter 5] and the related financial burden [Chapter 6], particularly 
in the Australian working population, and  
ii. To determine whether the current large national prevalence surveys are adequately 
designed for the surveillance of multimorbidity [Chapter 3-5]. 
7.1 Recap of Methods 
7.1.1 General recap 
The data presented in this thesis were collected from three different sources. The data 
used in Chapter 3 were derived from the NSMHWB-CURF 2007. The NSMHWB is 
a nationally representative household survey of 8,841 adults aged 18 to 65 years 
conducted by the ABS between August and December 2007. The ABS collected 
information on the presence of multiple chronic conditions based on Australian 
priority areas and on HRQoL using the AQoL instrument 1.  
The data used in Chapter 4 were derived from the 2011-13 nationally representative 
cross-sectional Australia NHS. The NHS was conducted by the ABS from March 
2011 to March 2012 and collected information on the presence of multiple chronic 
conditions, health care service utilization for each chronic condition and employment 
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status. This information allowed us to assess the health care needs of a representative 
sample of the Australian working population within the context of multimorbidity.  
The data used in Chapter 5 were derived from the 2013 pH@W survey of a 
representative sample of state government employees in Tasmania (n=3,228). This 
sample represented a typical public sector workforce, albeit with a higher percentage 
of females than the general Australian workforce (71.7% and 45% 2, respectively). 
The pH@W survey aimed to determine the needs of TSS employees. Therefore, 
generalizing these findings to all working Australians or to other working populations, 
should be performed with caution.   
Finally, the study presented in Chapter 6 involved a systematic search of COI studies 
on multimorbidity published in English from 2000 to 2016. The inclusion criteria: 
peer-reviewed, cross-sectional, cohort and modelling COI studies on multimorbidity. 
Studies focused on an index disease were excluded. The data extracted for each 
eligible study included the definition, measure, and prevalence of multimorbidity, the 
number of included health conditions, age range of the sample, COI methodology, 
proportion of multimorbidity costs, and the average costs per capita. The adapted 
British Medical Journal Checklist was used to assess the study quality. Costs were 
converted to USD using the 2016 exchange rate for each currency, with adjustments 
over time based on the Consumer Price Index.  
7.1.2 Definitions of multimorbidity 
Chapter 3 used count-based and cluster-based methods to identify multimorbidity 
using a pre-specified list of eight chronic conditions. In Chapter 4, multimorbidity 
was identified using a count-based method, using a cut-off value of “two chronic 
conditions” from a pre-specified list of eight chronic conditions; these conditions 
differed from those used in Chapter 3. The included conditions depended on the 
information collected in the surveys. In Chapter 5, multimorbidity was identified 
using a count-based method with a “two chronic conditions” cut-off value based on a 
pre-specified list of twenty chronic conditions. As no unique definition of 
multimorbidity exists, including the different definitions and measures in a systematic 
review was necessary and appropriate. Therefore, Chapter 6 did not specify the 
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definition of multimorbidity but summarized the costs of multimorbidity in terms of 
the definitions.    
7.2 Key findings  
7.2.1 Effect of multimorbidity definition on HRQoL 
The study reported in Chapter 3 is the first, to our knowledge, to compare number-
based and cluster-based definitions of multimorbidity using nationally representative 
data. This was achieved by determining the associations of multimorbidity with 
HRQoL, an important population health indicator. Based on a head-to-head 
comparison of a count and an alternative statistical approach to defining 
multimorbidity, this result is consistent with previous studies and validated the use of 
a hierarchical clustering approach when the outcome of interest is HRQoL. Moreover, 
this work established that a simple count fails to identify whether specific conditions 
of interest drove the occurrence of poorer HRQoL. Researchers should exercise 
caution when selecting a definition of multimorbidity as it may significantly influence 
the observed association with study outcomes. These findings advanced the literature 
by assessing the underlying driver of health status (multimorbidity) at the 
methodological level and confirmed that multimorbidity is a problem in the 
Australian general population. Prior to this epidemiological analysis with a head-to-
head comparison of health outcomes, the impact of multimorbidity in Australia was 
not well documented, particularly at the population level.  
The count-based method does not account for the type of chronic conditions present, 
and thus this method can determine the overall influence of multimorbidity on 
HRQoL but not the specific disease contributes to the associated HRQoL. The cluster-
based method, hierarchical clustering in particular, could capture the common clusters; 
a finding supported by sensitivity analysis, including factor analysis, principal 
component analysis and K-means clustering. Combining these findings validated the 
hierarchical clustering approach and proved it more useful and informative when 
HRQoL is the outcome of interest. However, future research is warranted to clearly 
describe the adopted definition of multimorbidity. 
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7.2.2 Associations between multimorbidity and HSU for arthritis and CVD 
After discussing multimorbidity in the general population, this thesis proceeded to 
address it in the Australian working population, which is a relatively healthier 
population and is central to the economic well-being of the country. To our 
knowledge, the study described in Chapter 4 is the first to examine the associations 
between multimorbidity and disease-specific healthcare service utilization in the 
workforce. Multimorbidity is known to increase the overall healthcare service 
utilization in the primary healthcare setting and in the general population, particularly 
in the elderly. However, in contrast to the existing studies, this study revealed 
multimorbidity also increased healthcare use in the working population, but single 
disease-specific healthcare use was not always positively associated with the 
existence of multimorbidity. Arthritis and CVD were the health conditions in the 
Australian workforce that showed higher healthcare utilization when comorbid with 
other chronic health conditions. This finding may inform future longitudinal research 
into when a higher burden of multimorbidity on HSU emerges for different 
combinations of disorders. These findings can also inform workforce health 
promotion interventions, and future research could focus on multimorbid employees 
living with arthritis or cardiovascular disease. Moreover, reforming health systems or 
policies to properly address these two health conditions may be beneficial, at least 
when focusing on the workforce.  
7.2.3 Associations between multimorbidity and absenteeism, presenteeism and total 
LPT  
In Chapter 5, this thesis explored the work attendance and productivity consequences 
of multimorbidity in the workforce. The definition of LPT has differed between the 
productivity measures used in the literature including absenteeism, presenteeism and 
total LPT, which is considered the sum of absenteeism and presenteeism. This study 
obtained all three estimates from employees’ self-reported data over a 28-day period, 
consistent with common measurements of LPT in the health field. The results showed 
a strong, positive association between the presence of multimorbidity and LPT. 
Additionally, having more chronic conditions was associated with greater LPT. These 
findings were consistent with prior evidence and suggest the management of single 
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health conditions in order to reduce health-related LPT may not, in fact, be tackling 
one of the strongest correlates of LPT-multimorbidity. Moreover, significant 
differences in LPT between men and women reporting multimorbidity were also 
identified. The female employees in in this public sector sample were more likely to 
report higher LPT   when facing chronic conditions compared to their female 
counterparts without chronic condition, while for male employees an association with 
LPT was not observed until four or more chronic conditions were reported.  
7.2.4 A systematic review of COI studies on multimorbidity 
The systematic review outlined in Chapter 6 was the first known attempt to compile 
information on the economic burden of multimorbidity. It is difficult to compare 
results across studies when the “disease” of interest is multimorbidity because the 
included studies differ in their definition and measurement of multimorbidity, the 
health conditions included, and the samples and economic estimates used. Therefore, 
the discussion was limited to describing the results but not pooling them.    
The main contribution of this review is the accumulation and summary of the 
available evidence on the costs of multimorbidity based on COI studies with 
standardized and acceptable methodologies and how the different methodologies were 
used. Further examination of the definition resulted in two opposite outcomes: 
exploring “multimorbidity” was not only with the count-methods even it was the most 
popular approach in COI studies, on the one hand, and reducing the comparisons 
between studies exactly due to different definitions of multimorbidity, on the other. 
This simple but important finding revealed multimorbidity cannot be managed 
without a clearer framework or better understanding of its definition.     
This study also found the methodology used to derive costs differed markedly 
between studies. The average annual costs per patient with multimorbidity ranged 
from $49-$252,313. Using a cut-off of two or more conditions, the proportional 
increase in cost for multimorbid compared to non-multimorbid ranged from 100% to 
1500% in the 17 available studies. The highest costs ($252,313) were found in a study 
of children in the US 3. Using a cut-off of three or more conditions, the average costs 
were 2-10 times the costs of those without multimorbidity in 12 studies. In the 10 
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studies providing a breakdown of costs, the largest proportion of costs was spent on 
inpatient care or prescriptions in studies with a non-societal perspective, whereas the 
largest proportion was on social care costs in studies from a societal perspective 4. 
These findings revealed that COI studies on multimorbidity are highly heterogeneous 
and that multimorbidity has been associated with a considerable economic burden. 
Referring to other COI reviews, the included studies were identified with good quality 
if the score was 7 and over (out of 10). Thirteen studies met this requirement and of 
them, only one study was with the best quality and scored 9. There were three studies 
conducted of children, with such studies rare due to the very low prevalence of 
multimorbidity amongst this age group. Those “extremely young” samples in 
multimorbidity were threatened by serious chronic conditions and some even died 
during the study, however, the results also showed the high costs for them in the 
following years, which was consistent with the findings from the other included 
studies. 
7.3 Implications of findings 
These findings have important implications for “multimorbidity” regarding HRQoL, 
HSU, LPT and the financial burdens, particularly in the working population. These 
studies were conducted with samples of the Australian population. However, as 
multimorbidity is now a common global health concern, the findings of this thesis 
may be relevant to “multimorbidity” settings at a fundamental level and could inform 
future research to address the identified gaps and shape health care systems. That said, 
all the studies presented in this thesis were cross-sectional, and thus no conclusions 
can be drawn regarding causality. 
The first implication of the results is theoretical. The study in Chapter 3 aimed to 
examine the performance of count-based and cluster-based definitions of 
multimorbidity regarding sociodemographic profiles and HRQoL in a general 
population. At the methodological level, multimorbidity does not have a single 
definition. Whilst there is a very general definition, i.e., “individuals who have two or 
more co-occurring chronic health conditions”, it does not allow for identification of 
multiple morbidity. For example, it does not specify whether the multiple conditions 
exist separately or could be causally linked. Therefore, without an index disease 
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‘multimorbidity’ could not appropriately address causally linked conditions while 
‘comorbidity’ could. Accordingly, this study performed head-to-head comparisons of 
definitions and confirmed the existence of an inverse relationship between 
multimorbidity and HRQoL in the Australian population. The analyses validated the 
hierarchical clustering approach when the outcome of interest was HRQoL, and found 
a simple count failed to identify whether there are specific combinations of interest 
driving poorer HRQoL. This finding suggests providing targeted health services to 
multimorbid individuals reporting only certain combinations, such as CVD and 
arthritis or MDD and anxiety disorder, may improve their HRQoL 5.  
However, the count method may still be useful to some extent because it is generally 
easy to estimate the number of conditions using many of the currently available 
datasets. Hierarchical clustering could be used as a supplementary tool in population 
or large administrative datasets to capture specific common clusters of multimorbidity. 
Regardless of which definition was adopted, an inverse association of multimorbidity 
with HRQoL was observed. This finding indicates multimorbidity is a problem in the 
Australian general population and a standard definition is needed.  
The second implication of the findings is practical in nature. The research to date 
has explored the consequences and quality of healthcare for multimorbidity in select 
population settings, including the primary healthcare and the elderly 6. This thesis 
initially focused on a non-selected population as the existing research indicates more 
people in the general/working population are living with multimorbidity without 
receiving appropriate treatment. For example, multimorbid individuals often receive 
conflicting medical advice for the different health conditions they are living with, or 
duplicate prescriptions from the different specialists 7, 8. Further, multimorbid 
individuals are sometimes advised to take prescription medications for different health 
conditions, by different specialists that have potentially harmful interactions without 
an understanding of the consequences 9, 10. 
Even with a certain working population, the findings of multimorbidity and LPT 
could help employers realize the value of maintaining a healthy working population, 
and can be considered by employers as they develop health benefits and preventive 
health care intervention strategies. While the severity of the increasing prevalence of 
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multimorbidity has been recognized, little is known about how to reduce the 
challenges in practice, due to a lack of knowledge about multimorbidity in the broader 
population rather than only in the older population or primary health care.  
This thesis provides new insights into the need for preventive strategies and improved 
treatment of people living with multimorbidity, which will become more and more 
important not only because of the global aging populations but also the aging 
workforces. There are care planning items for chronic disease that mainly focuses on 
the management of a single disease or the index disease and hence are insufficient for 
multimorbidity. And the primary care service which largely costs Australian financing 
system a lot is not very helpful for multimorbidity. The results of the currently 
available data highlight the need for future data collection and could also be helpful to 
aid in the design of a better functioning and financed health system for these people 
living with multimorbidity. 
Finally, the third implication of this relates to the global challenge of multimorbidity 
facing the health care field. Some international institutes, such as the NICE, the 
Academy of Medical Sciences, and the International Research Community on 
Multimorbidity (IRCMo), have started to improve access to existing knowledge, 
develop evidence-based strategies and facilitate international collaboration in research 
on multimorbidity. Of these institutes, the IRCMo has called for evidence to establish 
a consistent definition of multimorbidity to encourage an improved understanding of 
multimorbidity. NICE is more focused on developing relevant guidelines not only for 
clinical assessment and management but also for the working populations. This thesis 
highlights the fact that the currently available data in Australia restrict further 
exploration of multimorbidity.  
As a part of this thesis, it was originally planned to estimate the lifetime societal costs 
of multimorbidity in the Australian working population among workers who had two 
or more prevalent chronic conditions. That study planned to use cohort simulation and 
state-transition models to simulate the movement of a hypothetical cohort of the 
working population between health states over a lifetime according to the 
probabilities derived from a quality epidemiological data source and the existing 
literature 11. However, it was deemed unfeasible due to a lack of requisite inputs 
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related to the costs of multimorbidity. The AIHW confirmed that the national health 
care statistics were not currently collated in a format amenable to a study of this type. 
This valuable experience helped us rethink the methods of data collection to embrace 
the heterogeneity of multimorbidity. Therefore, future research on multimorbidity is 
warranted and should use research-friendly surveys, which allow the researchers 
access multimorbidity via various approaches within one dataset. 
7.4 Limitations 
Despite the strength of the studies conducted in this thesis and the aforementioned 
implications regarding HRQoL, health care service use, productivity loss and the 
related financial burdens, particularly in the working population, the limitations must 
also be considered. For example, the analyses conducted in this thesis were restricted 
to self-reported information. Further, the data source used did not link to medical 
records. Therefore, the results may be under- or over-estimates due to recall bias. For 
example, conditions such as mental disorders, are likely under-reported due to stigma, 
and behavioural disorders or diabetes often present as “silent” conditions, which could 
not be recognised by patients 12. That said, the samples used in this thesis were large. 
For example, the NSMHWB2007 included approximately 8,800 Australians, the NHS 
2011-12 included 20,250 Australians, and even the state- level data pH@W 2013 
included more than 3,000 Australian employees. The validity of self- reported chronic 
conditions has been indicated in different contexts 13-17. Moreover, self- reported data 
are cost-effective and convenient for gathering information in population-based 
surveys 18. These studies also progressed beyond the typical samples used in 
multimorbidity studies, which are often restricted to older or clinical populations.  
This thesis did not account for the severity of health conditions, which could prove 
useful in clinical settings 19, 20. However, national prevalence surveys of community-
dwelling populations tend to use a simple count method, rather than comorbidity 
measures, which weight conditions by their severity 21. There are two reasons for this: 
i) the weights of functional disease burden change by disease coding systems, and 
thus the scoring algorithms used to generate weights need regularly updating; and ii) 
the considerable costs of non-count methods are generally not feasible when 
conducting a national prevalence survey due to the additional respondent burden. A 
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further limitation is that the studies in Chapters 3, 4 and 5 excluded acute conditions 
6. Including more health conditions is more likely to provide a more comprehensive 
understanding of an individual’s health status, however, acute conditions were not 
considered in this thesis, because of the high probability of their temporarily impact 
on health status only 22 and therefore irrelevant to long-term health care planning.  
In addition to the shared limitations of the studies, each study has its own specific 
limitations. In Chapter 3, the data used were derived from a survey focused on mental 
health and well-being. So the assessments of chronic physical conditions were 
relatively brief, although consistent with many population prevalence surveys 23. In 
Chapter 4, the GP visits may be underestimated because some chronic health 
conditions are not serious and could be self-managed on a daily basis by patients 
themselves without any health care visits, especially in just a short period of one year. 
In Chapter 5, the survey used did not limit the measurement of productivity loss to the 
pre-specified health conditions. Therefore, employees may have reported on LPT due 
to other health problems. Hence, the impact of multimorbidity on productivity loss 
may have been underestimated. Further, recall bias may have been introduced as the 
rate of productivity loss was captured through the employees’ self-reported responses. 
However, the employees are in a better position than researchers to recognize, 
evaluate and rate their overall work performance based on self-reported evaluation. 
Moreover, previous research has shown that employees’ self-reported days lost are 
consistent with employers’ reported days lost 24.  
Another limitation worthy of note is that, this study obtained cross-sectional data in 
2013. Therefore, the direction of causality cannot be explored, and the results may 
only reflect short-term (four-week) employee behaviour, and the associations of 
multimorbidity with that behaviour. This methodology reduced the potential for recall 
bias of the self-reported questionnaire 25, as employees’ absenteeism or presenteeism 
behaviour may change over time. For example, based on our study, men may not 
currently be willing to take days off, but they may be more willing to do so at a later 
time, and after several years, they may ask for even more days off. However, this 
claim cannot be proven with cross-sectional data and requires further investigation 
using longitudinal data. For this reason, we presented the results as they were, in 
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contrast to one study, which annualized the same duration measures to reflect an 
entire work year 26.  
It is critical to note the increasing length of recall time may reduce the accuracy of 
estimation of the impact of health problems on their productivity by respondents 
themselves 25. However, if the focus of survey is on the frequency of productivity loss 
due to illness, the potential bias may be reduced 27. Finally, unlike the pathway to 
estimating the lost work time which did not distinguish the different types of lost time, 
the used pathway in Chapter 5 did not account for workers coming in early or leaving 
late on other days. Additionally, we surveyed a sample of TSS employees un-
representative of the total workforce. Moreover, pH@W used a self- report, short and 
simple measure to identify health conditions, which was commonly used in large 
population health surveys such as NHS 28 and NSMHWB 23.  
In Chapter 6, the results of this review were limited by the nature of the studies 
identified. The main limitation of this review was its inability to include all relevant 
studies. Costs were estimated in 16 countries or regions from 1996 to 2013. The large 
number of abstracts derived from the databases improved the sensitivity of our search 
strategy. The absence of a MeSH term for multimorbidity was a clear limitation. 
There was no published checklist for the quality of COI studies. Therefore, we 
adopted the modified British Medical Journal Checklist for authors and peer 
reviewers of economic submissions 29, which could help the BMJ editors improve the 
efficiency of the editorial process 30. The limitation of its scoring method was lack of 
weighting. Therefore, there was possible the scores were more likely affected by some 
items than others. Further works must be performed in these areas. However, adding 
multimorbidity-related terms from previous studies to our search strategy helped 
mitigate this limitation. We included papers published in English only, which 
restricted our sample.  
Moreover, the utility of COI studies in aiding policy decision making has been 
debated, 31, 32 and its inability to prioritize resources has been criticized 33, 34. COI 
studies serve a different purpose than health economic evaluations (e.g., cost-benefit, 
cost-effectiveness, and cost-utility analyses), which aim to describe the economic 
burden of a health condition on society which could potentially be avoided if the 
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condition is eradicated 35-37. COI studies can provide useful information as long as 
they adhere to standardized and acceptable methodologies 38, 39. Furthermore, the 
results of COI studies have been used by organizations such as the World Bank and 
the World Health Organization to estimate public, private and total national health 
expenditure on a global scale 40. Different stakeholders can utilize COI studies for 
different purposes 41. For example, for resource allocation purposes, governments 
may obtain the financial impact of a health condition on public budgets; whereas 
pharmaceutical companies are more interested in health condition with high 
management and direct research costs 41. However, caution is warranted when using 
COI studies. COI studies should be adopted in combination with other thorough 
economic evaluations in order to get optimal resource allocation 42. 
7.5 Recommendations for future research 
This thesis has provided evidence that multimorbidity is a common issue facing the 
Australian population and indicated that the relevant healthcare policies and systems 
should be modified accordingly. Specifically, research using multimorbidity-specific 
survey data is needed within the context of the current Australian healthcare 
framework to investigate the multi-directional multimorbidity and to support the 
development and refinement of current guidelines.  
Further, to improve the effectiveness and credibility of care management, research 
examining the overall health status of the general population living with 
multimorbidity, particularly studies using HRQoL to present health status, should 
include clusters of multiple health conditions, which could be captured by adding 
hierarchical clustering.   
Finally, data on the health service utilization of patients with multimorbidity, 
collected using a national representative sample, is required to identify comprehensive 
healthcare utility patterns rather than single chronic conditions, in order to better 
organize the limited health resources and optimize the input-output rate. Further, 
using a representative sample of the Tasmanian state service workforce, this thesis 
establishes that multimorbidity plays an important role affecting the productivity of 
employees, and hence suggests, support in the management of multimorbidity, and 
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that the Australian health system could and need to be improved. Because the indirect 
health costs are likely to be greater than the direct health costs and the population of 
multimorbid working adults are continuously growing. This also identified gender 
differences in multimorbidity-related lost productive time which should be considered 
in health planning for employees living with multimorbidity and how we organise the 
health system to support people with multimorbidity. Specifically, compared to their 
counterparts without any chronic conditions, female employees begin to report 
productivity loss when they have one chronic condition, whereas male employees are 
more likely to report productivity loss when living with four or more chronic 
conditions. However, the sample used is not representative of all Australian working 
population, meaning further research is required using a representative sample of 
Australian employees to investigate the potential association of work productivity loss 
with multimorbidity, and the impact of gender on this relationship.   
Further research is also needed to establish an approved list of health conditions 
which contribute to multimorbidity in different settings, which take into account local 
context, and regional differences. That said, regardless of which definition of 
multimorbidity is used, the included health conditions need to be chronic because in 
order to inform long-term health planning, and must also include the main four global 
chronic health conditions, cardiovascular diseases, cancers, chronic respiratory 
diseases and diabetes 43. An accessible, internationally recognised definition of 
multimorbidity is necessary to ensure global comparisons over time. Innovations in 
health system delivery for people with multimorbidity are being trialled in various 
settings. For example, nurse navigators or coordinators have been introduced to the 
health system in the state of Queensland to meet the complex needs of patients and 
help them “navigate” the healthcare system. Since 2015 an additional 400 experienced 
nurses have been progressively added to the state’s Hospital and Health Services over 
the next 4 years 44, 45. When facing the increasing population with multimorbidity, the 
efficacy of this service innovation is not yet known. This thesis indicated the specific 
groups with the relatively higher needs than others. Future research could be more 
focused on these groups. 
7.6 Summary and Conclusions 
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In conclusion, this thesis confirmed that multimorbidity is a significant public health 
problem in the general population, as well as in the workforce, and addressed three 
important gaps in the current understanding of multimorbidity.  
 The Theoretical Gap. Comparison of definitions identified the count method is 
still useful given its ease of calculation, but consensus is needed on whether a 
2-disorder or 3-disorder cut-off is most useful. Hierarchical clustering could 
be used as a supplementary tool to capture specific common clusters of 
multimorbidity. Most importantly, a uniform definition of multimorbidity is 
needed.  
 The Practical Gap. This thesis quantified the impact of multimorbidity on 
health care resource consumption in the Australian workforce and on 
productivity in a large Australian occupational cohort. The heavy economic 
burden of multimorbidity as demonstrated in the systematic review suggests 
that multimorbidity will be increasingly important in the future, especially 
considering the social changes related to delayed retirement. Moreover, this 
thesis has also shown and highlighted the tremendous financial implications 
for health care service design and delivery for meeting the needs of people 
living with multimorbidity. 
 The Methodological Gap. Results highlighted that currently available data 
restrict further explorations of multimorbidity. Standardization of the chronic 
disease surveillance methodologies used in national prevalence surveys would 
facilitate the epidemiological investigation of multimorbidity in the general 
population. Recommendations have been provided to improve the assessment 
and surveillance methods of multimorbidity at the population level.   
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